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ABSTRACT
Characterizing the Relation Between Depressive Symptoms
and Parkinson’s Disease in a Sample of Swedish Twins
Rebecca K. Widoe
Depression commonly co-occurs with Parkinson’s disease (PD). Psychosocial stressors and
biochemical changes associated with PD have both been implicated in the etiology of depression
in PD. The purpose of the current study was to examine whether genetic or environmental
influences contribute to the increased risk for depressive symptoms among individuals with PD
in a population of twins. Among individuals with PD, 24% endorsed a moderate-severe level of
depressive symptoms, and 64% endorsed at least a mild level of depressive symptoms. Casecontrol results indicated that PD is a significant risk factor for both mild (OR = 3.11, CI = 1.825.31) and moderate-severe (OR = 3.23, CI = 1.77-5.89) depressive symptoms, adjusting for age,
sex, and prior history of major depression. Odds ratios were not significantly attenuated in the
co-twin control analysis compared to the case control analysis for either mild or moderate-severe
depressive symptoms, suggesting that genetic influences are unlikely to account for the increased
risk of depressive symptoms among PD patients. Further support for environmental rather than
genetic influences on the PD-depression relation was revealed by examining the risk of
depressive symptoms among co-twins of PD patients versus co-twins of non-PD controls.
Controlling for age, sex, and prior history of depression, PD in the co-twin was not a risk factor
for mild or moderate-severe depressive symptoms in twins without PD. These findings indicate
that environmental influences likely play an important role in the etiology of depressive
symptoms in individuals with Parkinson’s disease. Alternatively, brain changes associated with
PD may heighten biological vulnerability to depressive symptoms.

Author Note
The purpose of the current study was to examine whether genetic influences contribute to
increased risk for depressive symptoms among individuals with PD, using a case control and cotwin control design. Of note, the original purpose of the study was to examine the role of genetic
and environmental factors in explaining the relation between depressive symptoms and PD. The
initial analysis plan included bivariate twin modeling and phenotypic comorbidity models to
decompose the variance in the PD-depressive symptom relation into genetic and environmental
components. Due to the lack of concordance for PD in the sample, however, twin modeling was
rendered uninformative. As such, the study aims were revised to evaluate PD as a risk factor for
depressive symptoms using an unrelated comparison group (classic case control study) and cotwin controls, allowing inferences to be drawn regarding the presence of a genetic influence
upon the risk for depressive symptoms within PD. The aims, hypotheses, and analyses presented
below are reflective of this change. As both the original and current designs allow investigation
of the role of genetics in the PD-depression relation, however, the overall goal of the study
remains the same: to shed new light on the etiology of PD-depression.
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Characterizing the Relation between Depressive Symptoms
and Parkinson’s Disease in a Sample of Swedish Twins
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder,
affecting roughly 0.3 percent of the US population (Barrero, Ampuero, Morales, Vives, de Dios
Luna del Castillo, Hoenicka, & Yébenes, 2005; de Lau, Giesbergen, de Rijk, Koudstaal, &
Breteler, 2004). PD is related to aging, however, and prevalence estimates increase to 4 to 5
percent for individuals of age 85 years and older (de Lau et al., 2004). For older adults, PD is the
second most frequent movement disorder, following essential tremor (Albin, 2006). Cardinal
features of PD include distal resting tremor, rigidity, bradykinesia, gait disturbance, and
asymmetrical onset (Rao, Hofmann, & Shakil, 2006). A progressive disorder, PD can lead to
disability and a decrease in quality of life.
Depression in PD
Community-based studies have found that psychological disorders such as anxiety and
depression are more common among individuals with PD as compared to healthy age- and sexmatched individuals (e.g., Tandberg, Larsen, Aarsland, & Cummings, 1996). Of the
psychological comorbidities associated with PD, depression is the most common (Cummings,
1992; Starkstein, Preziosi, Bolduc, & Robinson, 1990; Schneider, Althaus, Backes, & Dodel,
2008). Indeed, in James Parkinson’s original description of the “shaking palsy,” he described
“melancholy” as a central symptom of the disorder (Edwards, Kitt, Oliver, Finkelstein, Wagster,
& McDonald, 2002). Though prevalence estimates of depression in PD patients have ranged
from 4% (Hoehn & Yahr, 1967) to 70% (Bieliauskas & Galntz, 1989), recent reports document a
prevalence of major depressive disorder of approximately 8% in PD patients (Tandberg et al.,
1996), with clinically-significant depressive symptoms occurring in 35-50% of PD patients
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(Althaus et al., 2008; Cummings, 1992; Dooneief, Mirabello, Bell, Marder, Stern, & Mayeux,
1992). In the current proposal, depression in PD will be referred to as PD-depression.
Clinical presentation. Research suggests that PD-depression may present differently from
primary major depression. Specifically, the symptoms observed most frequently in PDdepression include irritability, difficulty concentrating, expressions of sadness and pessimistic
thinking, and a loss of interest in previously pleasurable activities (Cummings, 1992; Slaughter,
Slaughter, Nichols, Holmes, & Martens, 2001). Evidence also suggests that, compared to
primary major depression, PD-depression may be characterized by greater anxiety but less guilt
and self-blame (Barbas, 2006; Starkstein, Merello, Jorge, Brockman, Bruce, Petracca, et al.,
2008). Regarding suicidal behavior, research indicates that both suicidal ideation (Miyoshi,
Ueki, & Nagano, 1996) and suicide attempts (Merschdorf et al., 2003) are less frequent in PDdepression than in primary major depression.
Historically, PD-depression has typically been considered to be of mild severity, with
low to moderate levels of depressive symptoms (Cummings, 1992; McDonald, Richard, &
DeLong, 2003; Serrano-Dueñas, 2002). More recently, however, Ehrt and colleagues (2006)
compared the depressive symptoms of 145 non-demented depressed patients with PD to those of
100 elderly non-demented depressed individuals without PD, and found that depressive severity
was comparable for the two groups. Findings also revealed no significant difference in the level
of cognitive functioning between the PD and non-PD depressed groups, although depressed PD
patients did report more concentration problems than non-PD depressed patients. In contrast to
earlier studies that noted sadness as a frequently observed symptom in PD-depression, the
findings of Ehrt et al. indicated that depressed patients with PD less frequently reported feelings
of sadness. Depressed patients in the PD group also reported feelings of guilt, anhedonia, and
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loss of energy less frequently than depressed older adults without PD. Ehrt and colleagues
concluded that the differences in depressive symptom profiles for PD and non-PD individuals
may indicate that the brain changes of PD affect the clinical picture of depression. Specifically,
Ehrt et al. concluded that depression in PD may be more influenced by noradrenergic deficiency
than primary major depression, as noradrenergic depletion appears to disrupt concentration.
Taken together, the literature to date is inconclusive regarding whether PD-depression is truly
milder in form and different in symptom profile as compared to primary major depression.
Implications. The consequences of experiencing depression in PD are numerous.
Depression is a critical factor in the quality of life for PD sufferers (Behari, Srivastava, &
Pandey, 2005; Kuopio, Marttila, Helenius, Toivonen, & Rinne, 2000; Schrag, Jahanshahi, &
Quinn, 2000; Slawek, Derejko, & Lass, 2005), and has been associated with poorer cognitive
functioning among PD patients (Norman, Tröster, Fields, & Brooks, 2002; Uekermann, Daum,
Peters, Wiebel, Przuntek, & Müller, 2003). PD-depression also is associated with an
exacerbation of PD impairments, in both sensory and functional domains, as well as a steeper
decline in functioning (Chen, 2004; Nilsson, Kessing, Sørensen, Andersen, & Bolwig, 2002).
Hughes and colleagues (2004) reported that depression is related to an increased risk of mortality
for PD patients. In addition to the implications for the patient, PD-depression also presents an
increased burden for caregivers (Schrag et al., 2000). Finally, depression is a significant
predictor of the health care costs associated with PD (McCrone, Allcock, & Burn, 2007).
Considering the many negative effects of PD-depression, a fuller understanding of its etiology
may be an important step towards its prevention and treatment.
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Etiology of PD-Depression
Much empirical work has focused on understanding the etiology of depression in PD (see
reviews by Lieberman, 2006; McDonald et al., 2003; Slaughter et al., 2001; and Veazey, Aki,
Cook, Lai, & Kunik, 2005), particularly findings that contribute to the debate of whether
depression in PD is organic or reactive in nature. Historically, depression in PD has been
considered a reaction to the illness and disability of PD (Kearney, 1964). Chafetz and colleagues
(1955) conducted group therapy with a sample of PD patients and concluded that PD-depression
resulted from a denial of the PD symptoms due to an underlying fear of illness, disability, and
dependency. Psychodynamic research dominated early investigations into the psychological
aspects of PD and described tendencies for PD sufferers to have personalities that were
characterized as rigid, driving, worrying, and pessimistic (Booth, 1948; Sands, 1942); from a
psychodynamic perspective, an individual’s reaction to PD, including the development of
depression, would depend in large part upon his or her personality and childhood experiences
(e.g., abusive parenting). More recently, explanations for PD-depression have emphasized the
roles of biological (e.g., neurological, genetic) and psychosocial processes; evidence for these
etiological explanations will be examined next. Research regarding the issue of depression
preceding PD also will be presented, as depression that antedates PD may indicate either a risk
factor for PD or a prodromal symptom of the disorder.
Biological Hypotheses of PD-Depression
Neurological hypotheses. Neurological accounts of PD-depression posit that depressive
symptoms result from the neurodegeneration of PD. Researchers have argued that the
associations between higher depression rates and specific clinical characteristics of PD, such as
the akinetic rigid type of PD (Barrero et al., 2005; Starkstein et al., 1998) and right-sided motor
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symptoms (Starkstein et al., 1990), support a relation between PD-depression and the
neurodegeneration of PD (McDonald et al., 2003). The primary neurological or organic
explanations for PD-depression are the dopaminergic hypothesis and the serotonergic hypothesis.
The evidence for each hypothesis is presented below.
Proposed by Fibiger, the dopaminergic hypothesis is based upon the fact that, in addition
to the nigrostriatal, the mesocortical and mesolimbic dopaminergic projections also deteriorate in
PD (Fibiger, 1984). Fibiger hypothesized that it is damage to these projections that poses a risk
for depression in individuals with PD, as dopamine is considered one of three neurotransmitters,
along with serotonin and norepinephrine, involved in the pathophysiology of depression
(Weintraub et al., 2005). Empirical evidence for the dopaminergic hypothesis is currently
inconclusive, as some (Cantello et al., 1989; Torack & Morris, 1988), but not all (Broussolle et
al., 1999) imaging studies of PD-depression have indicated dopaminergic deficiency in the
mesocortical and mesolimbic dopaminergic projections, in addition to deficiency in the
nigrostriatal projections. More recently, Weintraub and colleagues (2005) examined the integrity
of the striatal dopamine transporter (DAT) in relation to PD-depression in a neuroimaging study,
and found that depressive symptoms were not reliably associated with overall DAT availability.
In contrast, Remy and associates (2005) examined the binding of the [11C]RTI-32 PET marker in
20 PD patients and found support for relations between deficiencies in both dopaminergic and
noradrenergic binding in the limbic system and PD-depression. Taken together, the research to
date offers conflicting findings regarding the dopaminergic hypothesis of PD-depression.
The serotonergic hypothesis, proposed by Mayeux and colleagues (1984, 1990), posits
that an overall reduction in serotonin levels occurs in PD to compensate for decreased striatal
dopamine, and that this reduction in serotonin presents a risk factor for depression. As with the
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dopaminergic hypothesis, findings regarding the serotonergic hypothesis are inconclusive. An
early study examining levels of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in
the cerebrospinal fluid (CSF) of depressed and non-depressed PD patients demonstrated
decreased 5-HIAA levels in the CSF of PD patients with major depression as compared to nondepressed PD patients, but no difference in 5-HIAA levels between dysthymic and nondepressed patients (Mayeux, Stern, Williams, Cote, Frantz, & Dyrenfurth, 1986). While
decreased 5-HIAA levels also were found in the CSF of depressed PD patients compared to nondepressed PD patients in a study by Kostic and colleagues (1987), results from the most recent
empirical examination of the serotonergic hypothesis do not support the hypothesis. Conducted
by Leentjens and colleagues (2006), the double-blind, placebo-controlled study experimentally
manipulated serotonin levels of PD cases and non-PD controls using an acute tryptophan
depletion (ATD) procedure, and found no evidence for a specific serotonergic vulnerability for
depression in PD patients. Replication studies of the ATD paradigm are needed before
conclusions regarding the serotonergic hypothesis of PD-depression are drawn.
Genetic hypotheses. A second category of biological hypotheses of PD-depression has
examined a potential genetic susceptibility for both depression and PD, as well as genetic
susceptibilities for PD-depression specifically. Regarding the heritability of depression, a recent
population-based study of major depression in Swedish twins found that heritability of liability
to major depressive disorder (MDD) was approximately 37% (Kendler, Gatz, Gardner, &
Pedersen, 2006b), an estimate consistent with other familial behavioral genetic studies (e.g.,
Middeldorp et al., 2005). Genetic factors also have been shown to influence liability to
depressive symptoms among older adults (Gatz, Pedersen, Plomin, Nesselroade, & McClearn,
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1992; Jansson et al., 2004). In contrast, estimates of heritability for PD are small and confined to
rare familial forms of PD (Warner & Schapira, 2003).
Regarding the heritability of PD-depression specifically, Fahim and colleagues (1998)
studied the familial aggregation of depression, dementia, and PD in a population-based sample of
6,596 individuals in order to investigate the possibility of a common, or shared, genetic origin
underlying the three disorders. Although their findings revealed a significant relation between
depression and a family history of psychiatric disorders in first degree relatives, no association
was found between depression and a family history of PD in first degree relatives, refuting their
hypothesis of a shared genetic origin for both depression and PD. More recently, however,
Arabia and colleagues (2007) investigated the possibility of a shared genetic susceptibility
between PD and depression by comparing the risk of depressive disorders among first-degree
relatives of PD patients to the risk of depression among first-degree relatives of controls. In their
population-based, historical cohort study, Arabia et al. did find an increased risk of depression
among first-degree relatives of PD patients compared to relatives of controls (hazard ratio, 1.54;
95% CI, 1.21-1.95, p < .001), and therefore concluded that depressive disorders may share
familial susceptibility factors with PD. As the two familial studies to date produced conflicting
findings, additional familial studies are needed to investigate a shared genetic susceptibility for
PD and depression
Genetic susceptibilities for PD-depression specifically also have been studied using
molecular genetic methodology. Barrero and colleagues (2005) conducted a study with 48 PD
patients and 41 age- and sex-matched controls to test for a genetic risk factor for depression in
PD related to the polymorphisms of the cannabinoid receptor gene (CNR1), which has been
implicated in depression and hypomanic features (Barrero et al., 2005). The rate of depression,
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as determined by categorization of scores on the Hamilton scale for depression (i.e., no
depression, mild depression, moderate depression, and severe depression), was not significantly
greater for PD cases than for controls. For PD cases, however, the presence of one or two short
alleles on the CRN1 genotype was associated with a significantly higher frequency of depression
(85.7%) than the presence of two long alleles (14.3%). The sample size for genetic analyses was
limited, however, as only 14 PD patients (29.2%) and five controls (12.2%) met criteria for a
diagnosis of depression. Also, analyses with non-PD controls did not find a significant role of
the genotype polymorphism for depression. Although the work of Barrero et al. (2005) provides
preliminary support that PD patients with short alleles in the CNR1 gene may be more
susceptible to PD-depression, additional molecular genetic studies with larger samples are
necessary to establish a firmer association between the cannabinoid system and PD-depression.
Finally, Burn and colleagues (2006) examined the hypothesis of a genetic susceptibility
to experiencing depression in PD by investigating allelic variation in a functional polymorphism
in the serotonin transporter (5-HTTLPR) gene. Their study was based on the possibility that
genotypic variability in the serotonergic system may account for the variable depression rates in
PD (Menza, Palermo, DiPaola, Sage, & Ricketts, 1999). Burn et al. examined the influence of
allelic variation in the 5-HTTLPR gene upon mood for 108 PD patients and 82 spousal agematched controls, and found no relation between either 5-HTTLPR genotype or allelic variation
and depression. They concluded that the 5-HTTLPR gene does not likely contribute to risk of
depression in PD. Taken together, the molecular genetic studies to date do not provide strong
support for a genetic origin of PD-depression.
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Psychosocial Hypotheses of PD-Depression
Contrasting the biological explanations, a psychosocial etiological hypothesis of PDdepression proposes that depressive symptoms in PD are “reactive,” or secondary to the
disability and/or psychological stress of the disease (Brown, MacCarthy, Gotham, Der, &
Marsden, 1988; Chen, 2004). McDonald and colleagues (2003) note that the stressors of
adjusting to a chronic illness and the accompanying life changes (e.g., loss of job, marital
discord), the awareness that PD treatments decrease in effectiveness over time, and the lack of a
cure for the disease may contribute to a reactive depression for some individuals. In a recent
qualitative study, Oehlberg and colleagues (2008) found that the majority of PD patients with
clinically significant depressive symptoms attributed their depression to psychosocial, rather than
to biological or PD-specific, factors. The evidence related to the psychosocial hypothesis of PDdepression is presented below.
Research that demonstrates the role of individual psychological factors upon distress and
mood disorders in PD has been used to support psychosocial etiological explanations of PDdepression. Allott and colleagues (2005), for example, argued that the role of metacognitive
style upon distress in PD refutes the notion that distress and mood disorders in PD are primarily
a consequence of neuropathology. They found that maladaptive metacognitive style, particularly
strong negative beliefs about worry, was a significant, independent predictor of distress beyond
PD disease factors such as age, disease severity, and disease duration. Allott et al. emphasize the
role of cognitions in the development and maintenance of emotional disorders, including anxiety
and depression; their research is based upon Wells and Matthews’ (1994) “self-regulatory
executive function model,” a model that stresses the role of negative beliefs (e.g., “worrying is
bad”) and responses (e.g., rumination) in the etiology of psychological disorders. From this
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perspective, it is possible that negative cognitive styles may predispose an individual to
“reactive” depression in PD. Alternatively, however, strong negative beliefs may arise from a
depressive state. Longitudinal studies are therefore needed to assess the temporal precedence of
metacognitive style, depressive symptoms, and PD onset before definitive conclusions may be
drawn regarding metacognitive style as a risk factor for “reactive” PD-depression.
Additionally, Moore and Seeney (2007) have identified certain biopsychosocial
predictors of depressive mood in PD patients. In a cross-sectional study that assessed various
correlates and predictors of depressed mood in 82 PD patients, blaming one’s self, avoidance,
and lack of recreational intimacy with one’s spouse or partner were significant predictors of
depressive mood, in addition to the PD characteristics of symptom severity and gross motor
impairment. The authors concluded that interventions aimed at increasing recreational intimacy,
reducing reliance on emotion-focused coping strategies, and educational programs on PD
symptoms would promote positive adjustment and improved mood among PD patients.
Although the individual psychological factors noted above likely influence mood in PD
patients, findings that PD sufferers have greater rates of depression than individuals with other
chronic illnesses with comparable disability levels (e.g., Ehmann, Beninger, Gawel, & Riopelle,
1990) argue against the theory that PD-depression is a reaction to the disability of the disease.
Additionally, greater rates of depression have been found in PD as compared to chronic and
disabling conditions that do not affect the central nervous system, such as arthritis and diabetes
(Edwards et al., 2002). It is possible that social support moderates the relation between disability
and depression in PD, though, as Simpson and colleagues (2006) recently demonstrated a
relation between less satisfaction with social support and greater rates of depression in PD.
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Depression in early-onset PD represents a subset of research with potential implications
for both the psychosocial and biological explanations of PD-depression etiology. Brown and
colleagues (1988) have suggested that patients with early-onset PD may be particularly
susceptible to depression due to experiencing greater financial and career disruption. Additional
psychosocial challenges associated with early-onset PD include greater marital and family
problems, higher rates of unemployment and early retirement due to disability, and stress from
living longer with the disease (Calne, Lidstone, & Kumar, 2008). Findings that patients with
early-onset PD (PD onset ≤ age 55) have increased rates of depression (e.g., Cole, Woodard,
Juncos, Kogos, Youngstrom, & Watts, 1996) have been interpreted as supportive of the concept
of reactive depression. Alternatively, however, early-onset PD may represent a subset of PD
sufferers that are uniquely predisposed to PD-depression or, as hypothesized by Starkstein and
colleagues (1989), depression may have a different etiology for early- vs. late-onset PD. While
the research to date (Giladi et al., 2000; Santamaria et al., 1986a, 1986b; Starkstein et al., 1989)
does indicate a relation between PD-depression and earlier age of PD onset that cannot be
explained by disease progression aspects such as severity, duration, and disability (Widoe, 2007),
the studies thus far have been correlational in nature and plagued by small sample sizes and
monomethod measures of depression assessment. As such, inferences regarding etiology of PDdepression based upon early-onset PD findings are inappropriate at this time.
Depression Preceding PD
Two additional alternative etiological explanation for PD-depression are the notions that
premorbid depression may either: 1) heighten the brain’s susceptibility to PD (e.g., depression as
a risk factor for PD), or 2) indicate an early non-motor manifestation, or prodome, of PD.
Ishihara and Brayne (2006) conducted a systematic review of studies that examined depression
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preceding PD diagnosis and concluded that, in three cohort studies and five of six case-control
studies, premorbid depression was significantly more common among PD cases than among
controls. The researchers hypothesized that both PD and depression are caused by similar,
underlying neuropathology, or that the neurological changes of depression predispose the brain
to be more susceptible to PD (Ishihara & Brayne, 2006).
Empirical findings demonstrating that depression predates PD diagnosis also have been
used to argue against the theory of reactive depression in PD. In a retrospective cohort study,
Schuurman and collaborators (2002) demonstrated that depression is a risk factor for the
development of PD even after controlling for age, sex, and socioeconomic status. Schuurman et
al. concluded that the serotonergic hypothesis of PD-depression is a reasonable explanation to
account for the association between depression and subsequent PD diagnosis, as patients may
have a biological vulnerability to the underlying mechanism of PD and premorbid depression
may represent a preclinical stage of PD. Although this hypothesis merits additional study, the
serotonergic hypothesis, as noted above, currently lacks strong empirical support. Furthermore,
it is possible that depression poses an environmental risk factor for the subsequent development
of PD, although no research to date has examined the extent to which premorbid depression may
explain depression in PD.
Taken together, research supports a relation between depression and subsequent
occurrence of PD, a finding that is not consistent with the notion that PD depression may be fully
explained as a psychosocial reaction to the illness. As patients have not yet been diagnosed with
PD, a psychological reaction to the diagnosis or disability cannot account for premorbid
depression. These findings could indicate either: a) depression predisposes an individual to the
development of PD either neurologically or environmentally, or b) depression prior to PD
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represents a pre-clinical manifestation of the disorder. Although a higher incidence of premorbid
depression in PD patients compared to non-PD patients has been documented in retrospective
register studies (e.g., Leentjens et al., 2003), the investigations to date have not concluded
whether premorbid depression operates as either a risk factor or a prodromal symptom of PD.
Determining whether depression that precedes PD represents a risk factor for PD or a pre-clinical
manifestation of the disorder has important implications for understanding the etiology, and
potentially the prevention, of PD.
Etiological Summary
Although there is support for a biological or organic etiology relating PD-depression to
the biochemical changes of PD (e.g., Mayberg & Solomon, 1995), other researchers have
highlighted the role of personal and social factors in explaining PD-depression as a reaction to
the disease (e.g., Brown & Jahanshahi, 1995). Of note, the two primary hypotheses of PDdepression as biological or psychosocial are not mutually exclusive (Veazey et al., 2005).
Findings that greater rates of depression occur in both the early and late stages of PD have been
cited as evidence that PD-depression results from a mixture of both subjective psychological
factors and underlying neuropathology of the disease (Veazey et al., 2005). The majority of the
reviews to date have concluded that PD-depression is most likely a combination of
environmental (e.g., psychosocial) and biological (e.g., neurochemical) changes. The etiology of
PD-depression remains unclear, however, and is the question driving the present study. The
proposed study seeks to advance science by investigating whether genetic influences contribute
to increased risk of depressive symptoms among individuals with PD, thereby informing theories
of the etiology of PD-depression.
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Statement of the Problem
Depression in PD is common and has several negative implications. Although several
risk factors for PD-depression have been investigated (e.g., genetic polymorphisms of CNR1,
clinical characteristics of PD, metacognitive style) to shed light on the etiology of PDdepression, no twin studies to date have examined whether genetic influences contribute to the
increased rate of depressive symptoms within PD. The current study therefore fills an important
gap in the literature by being the first study to explore depressive symptoms in PD in a sample of
twins. Furthermore, the two familial studies conducted to date to examine a possible shared
genetic susceptibility to PD and depression (Arabia et al., 2007; Fahim et al., 1998) have
produced conflicting findings, leaving the question of a shared genetic susceptibility to these
disorders unanswered. Finally, empirical investigations of PD-depression have predominantly
relied upon clinical, rather than population-based, samples. As findings from population-based
studies are more generalizable than findings from clinical studies (e.g., avoid the sampling bias
associated with recruiting from tertiary PD clinics), these findings may uniquely contribute to the
literature.
Further complicating the investigations to date, depression is also a risk factor for the
development of PD (Behari, Srivastava, Das, & Pandey, 2001; Hubble, Cao, Hassanein,
Neuberger & Koller, 1993; Kanner, 2005; Schuurman et al., 2002). Depression may be an early
manifestation of PD, a result of the neurodegeneration of the illness, a psychological reaction to
the diagnosis or disability of PD, or an amalgamation of two or more of these factors. Certain
factors (e.g., increasing age) also serve as risk factors for both PD and depressive symptoms and
the two phenotypes are both likely to have multifactorial causes. A better understanding of the
possible genetic influences upon the comorbidity between depressive symptoms and PD has
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etiological importance and, in turn, potential to inform preventative or treatment efforts. The
current study represents an important contribution to the literature on PD-depression by being the
first population-based twin study to evaluate PD as a risk factor for both mild and moderatesevere depressive symptoms.
Primary Aim
The primary aim of this study was to test whether genetic influences contribute to the
increased risk for depressive symptoms among individuals with PD, using a large, populationbased sample of twins. As noted above, several factors have been implicated in the etiology of
depression in PD, including the psychosocial stressors and biochemical changes associated with
PD. Twin studies provide a unique opportunity to examine whether an association is related to
genetic influences (Gatz et al., 2006). In the current study, multiple methods were utilized to test
whether genetic influences contribute to the PD-depression relation, after it was confirmed that
PD was a risk factor for both mild and moderate-severe depressive symptoms in the current
sample. In addition to examining the cross-twin cross-trait tetrachoric correlations for PD and
depressive symptoms, two different inferential statistical approaches were utilized to examine
whether genetic influences contribute to the increased risk of depressive symptoms among PD
cases. The first approach involved a case control and co-twin control analysis. The case control
design utilized all depressive symptom cases and examined PD as the exposure, or risk factor,
for depressive symptoms. The co-twin control analysis addressed potential concern about
genetic confounding, as this design used only unaffected co-twins as the control cases. If the
association between depressive symptoms and PD is attenuated when co-twins are used as the
control cases, a genetic contribution to the PD-depressive symptom relation is implied.
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Additionally, the co-twin control analysis was repeated using only monozygotic twins, to control
completely for genetic factors.
The second approach to test whether genetic influences contribute to the risk of
depressive symptoms among PD involved a logistic regression analysis to test, among
individuals without PD, whether co-twins of PD cases are at a higher risk of depressive
symptoms compared to co-twins of non-PD cases. This analysis tested whether PD status in
one’s twin increases personal risk of depressive symptoms, which would imply an underlying
genetic influence between PD and depressive symptoms. Conducting this logistic regression
analysis with only unaffected co-twins provides an inferential test to determine whether the
differences in the tetrachoric correlations are meaningful.
For the study’s primary aim – testing whether genetics contribute to PD’s role as a risk
factor for depressive symptoms – it was hypothesized that genetics would not contribute
significantly to the PD-depressive symptom risk. This null hypothesis for the role of genetics
was based on research findings that the etiology of PD is primarily environmental (Hardy, Cai,
Cookson, Gwinn-Hardy, & Singleton, 2006; Warner et al., 2003; Wirdefeldt, Gatz, Schalling, &
Pedersen, 2004) and on the inconclusive findings from familial studies of depression and PD
regarding a shared genetic origin for the two disorders (Arabia et al., 2007; Fahim et al., 1998).
As such, genetic influences were not expected to contribute to the risk of depressive symptoms
among PD patients. Specifically, it was not expected that the odds ratios for the co-twin control
analysis would be significantly smaller than the odds ratios for the case control analysis.
Regarding the unaffected co-twin analysis, it was not expected that PD status in one’s co-twin
would significantly predict an individual’s personal risk of depressive symptoms.
Secondary Aims
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Clinical presentation of PD-depression. A secondary aim of the current study was to
explore whether depressed PD cases responded differently to the depressive symptoms items, as
measured by the 11-item Iowa version of the Center for Epidemiological Studies – Depression
scale (CESD-I), compared to depressed individuals without PD. A series of ANCOVAs was
conducted to compare PD cases and non-PD cases on each depressive symptom on the CESD-I,
after controlling for age, sex, and overall level of depressive symptoms.
Early age of PD onset. Exploratory analyses also were conducted to examine whether
depressive symptoms were more likely for PD cases with an early age of onset (PD onset ≤ age
55) as compared to later, or more typical, age of onset. Age of PD onset is important to examine
because an earlier age of onset has been related to greater rates of PD-depression (e.g., Giladi et
al., 2000; Starkstein et al., 1989) in clinical samples, leading some researchers to conclude that
the etiology of depression may differ for early- versus late-onset PD patients. Also, as a greater
genetic influence has been suggested in the etiology of early-onset than for late-onset PD (Hardy
et al., 2006), it may be that, for early-onset cases, genetic factors influence the liability of PDdepression to a greater extent than for late-onset cases. Due to a limited sample size of earlyonset cases in the current dataset (i.e., 21 cases), these questions were explored descriptively in
the current study.
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Method
Participants
This study involved analysis of data from a study of Parkinson’s disease in the Swedish
Twin Registry (STR; Wirdefeldt, Gatz, Bakaysa, Fiske, Flensburg, Petzinger, et al., 2008). The
STR is a registry containing approximately 70,000 twin pairs born in Sweden between 1886 and
1990 (Lichtenstein, De Faire, Floderus, Svartengren, Svedberg, & Pedersen, 2002). Participants
for the Parkinson’s study were obtained through the Screening Across the Lifespan Twin study
(SALT; Pedersen, Lichtenstein, & Svedberg, 2002). The SALT study involved a complete
telephone interview screening of all cooperative twins born in 1958 or earlier who were alive at
the time of contact; a 73% response rate was obtained (Wirdefeldt et al., 2008). Detailed
information regarding the SALT data collection has been reported elsewhere (Lichtenstein et al.,
2002; Wirdefeldt et al., 2004). The Parkinson’s study population, 49,814 individuals, included
all twins eligible for the SALT who were at least 50 years of age by the date of their interview,
or if no interview was completed, the date of a letter notifying them of the SALT project.
Demographics. Relevant demographic variables collected include age, sex, and vital
status (i.e., living status or date of death). Demographic data for the study sample are presented
in Table 1. Consistent with twin samples from Sweden as compared to North American samples,
the percentage of dizygotic twins was greater than the percentage of monozygotic twins.
Zygosity. As detailed elsewhere (Lichtenstein et al., 2002), zygosity classification within
the STR was made using an algorithm of self-report questions regarding twin similarity (e.g.,
“How often did strangers have difficulty distinguishing between you and your twin partner when
you were children?”). Zygosity classification was validated in the SALT-pilot study using 13
DNA markers; the algorithm correctly classified zygosity in 99% of twin pairs (Lichtenstein et
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al., 2002). For the present study, twin pairs were classified as monozygotic, dizygotic – same
sex, dizygotic – opposite sex, or unknown zygosity. Zygosity data are presented in Table 1.
Twins with unknown zygosity were not included in the analyses.
Complete twin pairs vs. incomplete twin pairs. Complete PD data (i.e., status as PD case
or non-PD control) is known for 12,999 twin pairs. PD status is known for an additional 9,828
singletons (i.e., PD status is known for one twin of the pair). Using the CESD-I, complete
depressive symptom data is known for 12,229 twin pairs. Depressive symptoms are known for
an additional 9,504 singletons (i.e., depressive symptoms are known for one twin of the pair).
Measures
Depressive symptoms. An 11-item version of the Center for Epidemiological Studies –
Depression scale, the “Iowa form” developed by Kohout and colleagues (referred to in the
present report as the CESD-I; Kohout, Berkman, Evans, & Cornoni-Huntley, 1993), was used to
measure depressive symptoms. Respondents were asked to rate the frequency with which they
experienced 11 depressive symptoms (e.g., “I felt lonely”) during the past week on a 4-option
Likert scale ranging from 0 (Rarely/None – less than one day) to 3 (Most/All the Time – 5 to 7
days). Two items were reverse-scored. The range of possible scores is 0-33, with higher scores
indicating greater depressive symptomatology. If one or two items were missing, a prorated
score was calculated. Individual items are given in Appendix A. A cut-off score of 9 on the 11
items is utilized in the current study, as Gatz and colleagues (1993) demonstrated that this cut-off
best corresponds to the cut-off of 16 for the 20-item CES-D. In particular, a cut-off of 9 had a
sensitivity against the cut-off of 16 on the complete 20-item CES-D of 94.8%, with 84.3%
specificity.
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The full 20-item CES-D (Radloff, 1977) has good internal consistency (α = .89; Fiske,
Gatz, & Pederson, 2003) and fair stability, with test-retest correlations ranging from .51 to .67
tested over two to eight weeks (Radloff, 1977) and .61 tested over 3 months ( Devins et al.,
1988). The scale has strong concurrent and known-groups validities (Himmelfarb & Murrell,
1983; Radloff & Teri, 1986), and is an acceptable measure of depressive symptoms for older
adults (Fiske & O’Riley, 2007). Lewinsohn and colleagues (1997) have documented the efficacy
of the CES-D in identifying clinical depression, as confirmed by a diagnostic interview to
determine the presence of depressive disorder, among community-based older adults.
Kohout and colleagues (1993) tested the 11-item version of the CES-D against the
original 20-item measure in a sample of 10,296 individuals aged 65 and older and found that the
shortened version correlated well with the 20-item version (r = 0.95). Factor analyses indicated
that the shorter form assessed the same dimensions of depressive symptoms as the original CESD without significantly reducing reliability (Cronbach’s alpha = 0.81) (Kohout et al., 1993),
findings that have been replicated by Carpenter and colleagues (1998). In addition, using data
from the SALT pilot study, Suthers, Gatz, and Fiske (2004) demonstrated that the 11-item
version (CESD-I) provides meaningful information about depression in addition to depression
diagnoses, as assessed by the short form of the Composite International Diagnostic Interview –
Short Form (CIDI-SF; Kessler, Andrews, Mroczek, Ustun, & Wittchen, 1998).
Prior history of major depression. Both the short form of the Composite International
Diagnostic Interview –Short Form (CIDI-SF) and report of prior antidepressant use were utilized
to identify a prior history of depressive disorder. Specifically, prior history of major depression
was classified as either: 1) antidepressant use prior to SALT, or 2) an affirmative response to
either the dysphoria or anhedonia screening question on the CIDI-SF, in addition to a CIDI-SF
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score of 4 or greater. The CIDI-SF cut-off of 4 or greater has been shown to have adequate
agreement with the full criteria of major depression with the Structured Clinical Interview for
DSM-III-R (Kendler, Gatz, Gardner, & Pedersen, 2006a).
Procedure
PD diagnosis. As part of SALT, through population-wide screening of all Swedish twins
aged 50 years or older, the Parkinson’s study was designed to ascertain all cases of PD in the
STR (Wirdefeldt et al., 2008). Twins in the study population were ascertained for PD in three
phases. Please refer to Figure 1 for an overview of the study design.
In the first phase, twins were screened for PD and PD symptoms by telephone as part of
SALT. In the second phase, twins who were PD suspects due to symptoms related to diseases
other than PD were excluded from further follow-up. Twins with suspected PD in the SALT
interview were given a second telephone interview including detailed questions about PD
symptoms and other diseases. The third phase involved clinical evaluations of twins who were
still suspects after the second screening, twins with self- or proxy-reported PD from SALT, twins
with suspected PD from a previous dementia study (HARMONY), and a sample of co-twins.
Each of the three phases of PD ascertainment is elaborated upon next.
Phase 1: SALT screening. Between 1998 and 2002, all living twins born in 1958 or
earlier were contacted using computer-assisted telephone interviews. The interview included a
checklist of common diseases including PD, as well as a series of questions specific for PD
(originally developed by Tanner, Ellenberg, Mayeux, Ottman, & Langston, 1994) that was
administered to individuals aged 50 or older by the date of their interview. These questions were
about the use of anti-parkinson medication and a variety of PD symptoms.

21

PD symptoms included trouble arising from a chair, small handwriting, poor balance, feet
getting stuck to the floor, little facial expression, shaking arms or legs, difficulty buttoning
buttons, shuffling feet or taking tiny steps when walking, soft voice and slow movements. If the
twin said “yes” to two symptoms or more, the twin was asked age of onset and whether onset
was gradual or sudden. If it was not possible to talk to the twin (for example, due to cognitive
impairment or hearing problems), interviewers requested to speak with a proxy. In these cases,
questions about a previous PD diagnosis and anti-parkinson medications were included, but
questions about PD symptoms were omitted. Of 49,814 individuals aged 50 years and older
eligible for SALT, 36,197 (72.7%) responded to the interview either themselves or through a
proxy. In total, 36,033 individuals responded to the specific questions about PD, 35,031 (97.2%)
themselves and 1,002 (2.8%) through a proxy.
To identify twins who exhibited early symptoms of PD but who did not report having
received a PD diagnosis, an algorithm was constructed to evaluate responses to the PD symptom
questions in SALT. This algorithm was intended to map onto the diagnostic criteria for PD
based on results from previous validation studies of screening questions (Wirdefeldt et al., 2008).
Twins were considered positive for the “parkinsonian algorithm” if they said “yes” to the
symptom shaking arms or legs plus “yes” to one of the following four symptoms: small
handwriting, feet stuck to the floor, difficulty buttoning buttons, and soft voice. A second
algorithm, referred to as the “bradykinesia algorithm,” also was constructed in order to capture
PD cases characterized by bradykinesia but not resting tremor. Twins were considered positive
if they said “no” to the symptom shaking arms or legs and “yes” to three of the four symptoms
mentioned above. Those who reported sudden onset of symptoms, multiple sclerosis, polio as a
child, or neuroleptic drug use were excluded prior to the second phase.
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Taken together, in the first phase, 637 twins were considered PD suspects from SALT
based on the symptom algorithms described above or anti-parkinson medication use, and 60 had
been worked up in the HARMONY study and they were therefore not contacted for the second
screening. An additional 57 twins were not contacted due to an administrative error. Of the
remaining 520 PD suspects, 452 were alive and had agreed to be contacted further by the STR.
Phase 2: Second screening to exclude obvious non-PD. Beginning in May of 2002, PD
suspects from SALT were contacted again for a second screening interview. The purpose of this
interview was to make the clinical work-up process more efficient by excluding PD suspects
from further follow-up who reported symptoms and PD medication due to diseases other than
PD. Twins who were positive for the parkinsonian algorithm in SALT were excluded from
further follow-up if they screened negative for resting tremor, or if they screened positive for
resting tremor and negative for bradykinesia. Twins who were positive for the bradykinesia
algorithm in SALT were excluded from further follow-up if they screened negative for
bradykinesia. If the twin said “yes” to a cardinal symptom, follow-up questions were asked
aimed at identifying any reasons for reporting the symptom that were clearly not related to
parkinsonism, in which case the symptom was considered negative for screening purposes.
Twins who were on regular neuroleptic treatment prior to the onset of symptoms also were
excluded. To be excluded, the twin had to say “no” to the question about PD diagnosis and “no”
to anti-parkinson medication. Answers to the second screening interview for PD suspects, who
were not excluded by the exclusion algorithm, were reviewed by the study physician. On the
basis of that review, additional PD suspects were excluded, in some instances due to simple
misunderstandings in the initial SALT interview (for example, one twin reported a PD diagnosis
when actually his wife had PD), and in other instances due to obvious reasons for reporting
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parkinsonian symptoms other than PD (e.g., hydrocephalus or previous severe brain trauma). In
the latter cases, information from medical records also was available.
In the second screening phase, 349 PD suspects participated (corresponding to a
participation rate of 77.2%), 203 (58.2%) were excluded from further follow-up due to their
answers to the second screening questions, 182 directly by the exclusion algorithm, and 21 after
review of answers by the study physician. Details regarding non-participation have been
reported by Wirdefeldt et al. (2008). Of the 60 PD suspects worked up in HARMONY, 53 twins
(88.3%) were excluded based on the neurological examination that was part of their dementia
workup. In total, 146 twins were still considered a PD suspect after completing the second
screening interview, and an additional 7 PD suspects from HARMONY also remained, for a total
of 153 PD suspects.
In the second screening interview, attempts to contact co-twins of twins with suspected
PD and co-twins of twins with self-reported PD who participated in the second screening were
made, so that twin pairs would have equivalent screening. Among co-twins of the 153 twins
with suspected PD, ten were PD suspects themselves, resulting in 143 co-twins who were
contacted. Of 154 twins with a self- or proxy-reported PD diagnosis in SALT, 131 participated
in the second screening interview and two of these had co-twins who were themselves probands,
resulting in 129 co-twins who were contacted. Of these 272 co-twins, 19 were already included
in HARMONY, 61 were dead, and 24 refused SALT and were therefore not contacted again. Of
the remaining 168 co-twins, 134 (79.8%) participated in the interview, 23 refused, five could not
be reached, two were not possible to interview, and four were not contacted due to administrative
error.
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Phase 3: Clinical work-up. The 154 twins with self- or proxy-reported PD in SALT, the
34 twins with PD suspicion by HARMONY, and the 153 twins still considered PD suspects after
the PD second screening interview were referred for a clinical work-up in the third phase. In
addition, the first 102 co-twins also were referred for a clinical work-up. As detailed below, for
most of the PD suspects and co-twins, the clinical work-up consisted of an in-person somatic
examination in addition to medical record review; for most of the twins with self- or proxyreported PD, the clinical work-up was based on medical record review alone plus telephone
interview.
The in-person clinical work-up consisted of a home visit by the study physician for a
complete neurological examination with relevant signs and symptoms, general somatic and
psychiatric examinations, an inventory of current medications, and medical history. Average
duration of a visit was two hours. The Unified Parkinson’s Disease Rating Scale (UPDRS; Fahn
et al., 1987) was used to evaluate parkinsonian signs and symptoms. The examination was
documented on video according to a standardized protocol. Twins with suspected memory
problems were evaluated by neuropsychological testing and proxy interviews.
Of the 153 PD suspects after the second screening, 119 (77.8%) underwent a somatic
examination and 15 (9.8%) were worked up by medical records. Of the 19 remaining PD
suspects, 11 did not have a diagnostic work-up because they refused, seven died after the second
screening, and one was not worked up due to logistical difficulties. An additional two twins who
were considered PD suspects after SALT but did not participate in the second screening were
also worked up. Diagnostic work-ups were completed for 102 co-twins, 97 by somatic exam,
and 5 by medical records.
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For the 188 twins with self- or proxy-reported PD in SALT or PD suspicion by
HARMONY, the clinical work-up consisted of a review of all relevant medical records. A nurse
also performed a telephone interview with these twins, including detailed questions about
symptom onset and manifestation of the disease. For twins who died between screening and
clinical work-up, a modified interview was performed with a relative. Twins with insufficient
information in medical records to assign a diagnosis, or with a record of PD diagnosis only by a
general practitioner, were visited by the study physician according to the same protocol as the
PD suspects. PD diagnostic work-ups were completed for 182 of the 188 twins (173 by medical
records only and nine by somatic exam in addition to medical records). In the remaining cases, a
diagnosis could not be assigned due to insufficient information (for example, medical records
could not be obtained).
Assignment of Parkinson disease diagnoses. Diagnoses based on somatic exams were
assigned by the study physician, together with a movement disorder specialist. Another
movement disorder specialist independently assigned diagnoses based on reviewing the
videotaped examination and the notes made during the somatic exam. Cases in which there was
disagreement between the study physician and the diagnosis based on the videotaped
examination were reviewed by a third movement disorder specialist. Final consensus diagnoses
were all agreed upon by two movement disorder specialists. Diagnoses based on medical
records were assigned by the study physician, together with one movement disorder specialist.
The National Institute of Neurological Disorders and Stroke (NINDS) diagnostic criteria for PD,
described in Appendix B, were used to classify possible and probable PD. Consensus clinical
diagnoses for the study population are shown in Table 2 (Wirdefeldt et al., 2008). Ninety-nine
twins with probable PD (mean age of onset: 64.3 years ± 10.6 years, range: 39 – 90) and 33
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twins with possible PD (mean age of onset: 71.7 years ± 8.5 years, range: 44 – 88) were
identified. Individuals with diagnoses of parkinsonism, rather than PD, were included in the
current study, but were classified as non-PD.
Definition of PD cases. All twins diagnosed with possible or probable PD by diagnostic
work-up were regarded as PD cases, for a total of 132 cases. More detailed information about
PD case ascertainment in the STR has been recently presented elsewhere (Wirdefeldt et al.,
2004; Wirdefeldt et al., 2008). Because the STR is population-based, the risk of ascertainment
bias was minimal compared to other sampling strategies (Wirdefeldt et al., 2004).
For the proposed study, of the 49,814 individuals in the study population, PD status (i.e.,
PD or not-PD) was known for 35,681 individuals (71.63%). Of the 35,681 individuals for whom
PD status was known, 132 (0.37%) had PD and 35,549 (99.63%) did not have PD. The
proportion of the study population for which PD status was unknown (28.37%) was attributable
primarily to non-participants in the SALT screening phase (e.g., refusal to participate, death prior
to SALT).
Of note, only individuals whose PD onset was prior to the SALT interview were included
in the current study, to ensure concurrence of measurement time for PD and depressive
symptoms. For 7 of the 132 PD cases, the onset of PD was after the SALT interview, reducing
the sample to 125 PD cases. Of these 125 cases, CESD-I information was available for 96
individuals. For the 29 PD cases missing depression information, 12 had a comorbid diagnosis
of dementia, precluding the collection of CESD-I data.
Rearing status was descriptively examined for the PD cases, to assess possible
differences in concordance rates for PD cases reared together compared to reared apart. Of the
125 PD cases, 4 were reared apart from their co-twins; all four were dizygotic twins. Of these
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four, three of their co-twins were classified as non-PD and one co-twin was missing information
on PD status. Due to the limited number of PD twins reared apart from their co-twin, it was not
possible to conduct analyses separately for PD twins reared together versus reared apart. On
visual inspection, the records for these four twins revealed no apparent systematic differences
from the records of PD twins reared with their co-twin.
Definition of depression cases. Depressive symptoms were assessed by the 11-item CESD, or CESD-I. Moderate-severe depressive symptom cases were identified as those participants
who met the clinical cut-off of 9 or greater on the CESD-I. Overall, depressive symptom status
was known for 33,910 (68.07 %) in the study population. As with the missing PD status,
depressive symptom totals are unknown primarily for non-responders in the SALT screening
phase. Of the 33,910 individuals for whom depressive symptoms are known, 4,024 (11.87%)
had clinically significant depressive symptoms (CESD-I total score ≥ 9) and were considered
moderate-severe depressive symptom cases in the current study. The status of the remaining
29,886 (88.13%) individuals was non-depressive symptom cases.
Two different cut-off points were used to determine depressive symptom status in the
current study, and analyses were conducted for both definitions of depressive symptom status.
The first cut-off, described above, defined clinically significant depressive symptoms as a score
of 9 or greater on the CESD-I. Because depression in PD is usually considered to be of milder
severity than primary major depression, however, (Cummings, 1992; McDonald et al., 2003;
Serrano-Dueñas, 2002) and prevalence estimates of PD-depression typically range from 40-50%
(e.g., Tandberg et al., 1996; Wichowicz, Slawek, Derejko, & Cubala, 2006), all analyses were
repeated with a cut-off that defined clinically significant depressive symptoms as the CESD-I
total score that most closely approximated the upper 40% of CESD-I scores in the current PD
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sample. Because CESD-I scores ≥ 4 represent the top 38.1% of CESD-I scores in the sample, a
score of 4 or greater was used as the second cut-off point used to determine mild depressive
symptom status. In addition to its relevance for PD patients, milder, or sub-threshold, depressive
symptoms have been shown to have a variety of clinical implications for older adults (e.g.,
Horowitz, Reinhardt, & Kennedy, 2005; Rollman & Reynolds, 1999). There is also evidence
that major and minor depression among medically ill older adults varies by prior history of
depression (Koenig, 1997), one of the covariates in the current study. As such, the use of two
CESD-I cut-offs was employed to allow examination of both mild and moderate-severe
depressive symptoms.
Covariates. Age and sex were included as covariates in all case control analyses. Age
and sex were controlled for by design in co-twin control analyses with same sex pairs. For both
case control and co-twin control analyses, prior history of major depression was added as a
covariate.
Statistical Analyses
Concordance rates and correlations. Probandwise concordance rates were calculated to
explore whether twin similarity for the PD phenotype, moderate-severe depressive symptoms
phenotype, and mild depressive symptoms phenotype differed by zygosity. Probandwise
concordance is an index of familial resemblance for dichotomous traits, and can also be
interpreted as the risk one has to develop a disorder if one’s twin has the disorder (Plomin,
DeFries, McClearn, & Rutter, 1997). If members of a twin pair both have PD, for example, they
are considered to be concordant for the disorder. If only one member of a twin pair has PD, the
pair is discordant for the disorder. A pattern of greater MZ concordance rates compared to DZ
concordance rates is suggestive of a genetic influence upon a phenotype.
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Two types of tetrachoric correlations were estimated: within-trait tetrachoric correlations
and cross-twin cross-trait tetrachoric correlations. First, within-trait tetrachoric correlations were
calculated separately for: 1) PD cases, 2) moderate-severe depressive symptom cases, and 3)
mild depressive symptom cases. Within-trait tetrachoric correlations indicate the extent to which
twin pairs are similar for a phenotype, providing information about univariate heritability. These
correlations were conducted for the MZ, same-sex DZ, and opposite-sex DZ twin pairs. Withintrait tetrachoric correlations were calculated to detect the similarity of twins within a pair;
genetic effects are implied if MZ twins display higher tetrachoric correlation coefficients than
DZ twins.
Second, cross-twin cross-trait tetrachoric correlations were calculated to provide
information about the genetic influence upon the relation between PD and depressive symptoms.
Specifically, cross-twin cross-trait correlations indicate the extent to which PD in one twin is
informative of depressive symptoms in the other twin. To the extent that MZ twin pairs have
greater cross-twin cross-trait similarity compared to DZ twin pairs, genetic influence on the
comorbidity, or relation, between PD and depressive symptoms is implied. Additive genetic
effects are implied if the tetrachoric correlation is doubled in MZ pairs compared to DZ twin
pairs, as MZ twins share 100% of their genetic material and DZ twins share approximately 50%
of their segregating genes.
Case control and co-twin control analyses. Odds ratios were calculated to estimate the
relative risk for depressive symptoms given PD status as the exposure. The association between
depressive symptoms and PD was analyzed in the case control design using alternating logistic
regression (ALR), utilizing all controls. First, the odds ratio (OR) and 95% confidence intervals
(CI) for PD as a risk factor for depressive symptom status was estimated controlling for age and
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sex. Second, the OR and CI for PD were estimated with prior history of major depression
included as an additional covariate. Confidence intervals were adjusted using robust standard
errors for having two members from the same family included in the analysis, to correct for nonindependence of observations. The adjustment was achieved by use of a SAS macro. The macro
increases the variance estimates in magnitude proportional to the degree of correlation between
twin pairs. This procedure effectively widens the confidence intervals to be more conservative
(Gatz, Mortimer, Fratiglioni, Johansson, Berg, Reynolds, et al., 2006; Lin, 1994).
In the co-twin control analyses, odds ratios were obtained from conditional logistic
regression, using twin pair as a stratification variable. Co-twin analyses utilized all discordant
depressive symptom cases and their co-twins. By design, a co-twin control analysis controls for
sex and age; prior history of major depression was added as a covariate. The test provides an OR
and 95% confidence interval based on Wald tests. In addition, co-twin control analyses were
repeated using monozygotic twins (MZ) only. As MZ twins share 100% of genes, this test fully
controlled for unmeasured confounding by genetic effects.
Unaffected co-twin analysis. Logistic regression analyses were conducted to test whether
PD status in one’s twin increased personal risk for mild or moderate-severe depressive
symptoms, after controlling for age, sex, and prior history of depression. This analysis provides
a statistical test of whether genetic influences are operating in the relation between PD and
depressive symptoms. The sample used included all co-twins of PD cases in discordant pairs, as
well as one randomly-selected twin from each pair in which neither twin had PD.
Supplementary analyses. As a preliminary analysis, intra-class correlations were
conducted on total depressive symptom scores, by zygosity. In addition, for each symptom on
the CESD-I, an ANCOVA was conducted to compare PD cases and non-PD cases, after
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controlling for age, sex, and overall level of depressive symptoms. All analyses were conducted
using SAS 9.1.
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Results
Preliminary Analyses
Prevalence rates. Prevalence rates for cases with mild depressive symptoms (CESD-I ≥
4) and cases with moderate-severe depressive symptoms (CESD-I ≥ 9) are shown in Table 3.
The prevalence rates for both mild and moderate-severe depressive symptoms were greater
among the PD cases than the non-PD individuals. For mild depressive symptoms, the prevalence
rate was 63.54% (61/96) for PD cases, a significantly greater rate (X2 = 28.57, p < .0001, df = 1)
compared to the prevalence rate of 37.13 % (12,394/33,377) among individuals without PD.
Similarly, for moderate-severe depressive symptoms, the prevalence rate was significantly
greater (X2 = 14.56, p < .0001, df = 1) among PD cases (23.96%, or 23/96) compared to non-PD
cases (11.50%, or 12,394/33,377).
Prevalence rates also were calculated separately for individuals with early-onset PD
versus those without an early age of onset, to descriptively explore whether early-onset PD may
be a risk factor for depressive symptoms. Of the 125 PD cases, 21 individuals (16.8%) had a PD
age of onset at 55 years or earlier. Depressive symptom status was available for 17 of these 21
PD cases. For early age of onset, the rate of moderate-severe depressive symptoms was 35.29%
(6/17) compared to a rate of 22.08% (17/77) for cases with later age of onset. The rate of mild
depressive symptoms was roughly equivalent, however, for individuals with early age of onset,
as 35.29% (6/17) of early-onset cases met criteria for mild depressive symptoms, compared to
38.96% (30/77) for PD cases with later age of onset. Although definitive conclusions are
precluded due to the small number of early-onset cases, it is notable that early age of PD onset
was associated with a higher rate of moderate-severe depressive symptoms in this populationbased sample, whereas rates of mild depressive symptoms did not differ by age of PD onset. Nor

33

was early age of PD onset associated with prior history of major depression (0/16 early-onset
cases had a prior history of depression, while 4/72 later-onset cases had a prior history of
depression).
Concordance rates. Probandwise concordance rates are shown in Table 4. Of the 125
PD cases, there were 3 concordant pairs: 1 MZ pair, and 2 DZ pairs. The lack of attenuation in
the PD concordance rates for dizygotic twins as compared to monozygotic twins suggests that
genetic influences are unlikely in the etiology of PD. Conversely, for both mild and moderatesevere depressive symptoms, slight attenuation is observed in the concordance rates by zygosity,
suggesting some genetic influence in the etiology of these phenotypes.
To address one of the secondary study aims, it was originally planned that concordance
rates for PD would be calculated separately for early-onset PD (i.e., PD onset at age 55 or
younger) and later-onset PD, to explore whether heritability differed significantly for early
versus late PD onset. This secondary analysis was rendered uninformative, however, as none of
the six twins within the three concordant pairs had an early age of PD onset. For these
individuals, age of PD onset ranged from 63 – 76 years of age.
Tetrachoric correlations. The within-trait tetrachoric correlations are shown in Table 5.
Results revealed attenuation in the within-trait correlation by zygosity for both mild and
moderate-severe depressive symptoms, suggestive of a genetic influence upon these phenotypes.
For PD, within-trait correlations did not significantly differ by zygosity, suggesting a lack of
genetic etiology of PD.
The cross-twin cross-trait tetrachoric correlations are shown in Table 6. For PD and
moderate-severe depressive symptoms (CESD-I ≥ 9), the cross-twin cross-trait tetrachoric
correlations did not differ by zygosity, suggesting lack of a genetic influence upon the PD-
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moderate-severe depressive symptom comorbidity. The cross-twin cross-trait tetrachoric
correlations also did not markedly differ by zygosity for PD and mild depressive symptoms
(CESD-I ≥ 4).
Intra-class correlations. Intra-class correlations were calculated on total CESD-I scores
as a continuous measure of depressive symptoms, for the entire sample, by zygosity. These
results suggested a genetic influence on total depressive symptom score, as the intra-class
correlation was greater for MZ twins (r = 0.28, p < .0001) as compared to DZ same-sex twins (r
= 0.13, p < .0001) and DZ opposite-sex twins (r = 0.07, p < .0001).
Case Control & Co-Twin Control Analyses
Moderate-severe depressive symptoms (CESD-I score ≥ 9). In the case control analyses,
alternating logistic regression results provided in Table 7 confirm that PD was a significant risk
factor for moderate-severe depressive symptoms, after controlling for age and sex. Odds ratios
adjusted for prior history of major depression revealed that PD is a stronger risk factor for
moderate-severe depressive symptoms after this adjustment. The odds ratio for the co-twin
control analysis compared to the case-control analysis was not greatly attenuated (3.15 compared
to 3.23), suggesting that genetic associations are unlikely to account for the relation between PD
and moderate-severe depressive symptoms. When co-twin control analyses were conducted
using only MZ twins, the results did not differ from using all co-twins; although this may be seen
as evidence for no genetic influence upon the PD-moderate-severe depressive symptom relation,
the low number of monozygotic PD cases precludes this conclusion.
Mild depressive symptoms (CESD-I score ≥ 4). In the case control analyses for mild
depressive symptoms, alternating logistic regression results provided in Table 8 confirm that PD
was also a risk factor for mild depressive symptoms, with and without adjusting for prior history
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of major depression. As with depressive symptoms at the level of 9 or greater, PD did not have a
significantly lower odds ratio for mild depressive symptoms for the co-twin control analysis as
compared to the case control analysis (3.22 compared to 3.11). For the co-twin control analysis
conducted with only MZ pairs, PD was no longer a significant risk factor for mild depressive
symptoms, although the limited number of PD cases in this analysis and the resulting decrease in
power likely contributed. Taken together, this pattern of results suggests that genetic influences
are unlikely to account for the increased risk of mild depressive symptoms among PD cases.
Unaffected Co-Twin Analysis
Logistic regression results indicated that co-twin PD was not a predictor of moderatesevere depressive symptoms when controlling for age and sex (Wald = 3.09, p = .08) or when
controlling for age, sex, and prior history of depression (Wald = 2.89, p = .09). Co-twin PD also
did not predict mild depressive symptoms after controlling for age and sex (Wald = 0.18, p =
.07) and when controlling for age, sex, and prior history of depression (Wald = 0.15, p = .70).
Because co-twin PD did not relate to twin depressive symptom status, it is unlikely that shared
genetic influences are operating between PD and depressive symptoms.
Supplementary Analyses
Clinical presentation of PD-depression. Results from the ANCOVA analyses for each
depressive symptom, after controlling for age, sex, and overall level of depressive symptoms, are
shown in Table 9. As the results from twin 1 and twin 2 were substantially the same for each
symptom, the results reported are from twin 1. Of the eleven CESD-I item ANCOVAs, PD
status was a significant predictor of higher scores for item 3 (“I felt sad”), F (3, 16789) = 4.93, p =
0.03, and for item 7 (“I couldn’t get going”), F (3, 16782) = 6.83, p = 0.01.
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Discussion
The current study advances the field of PD-depression by being the first study to use a
twin sample to examine the role of genetics upon the increased risk of depressive symptoms
within PD patients. In addition, the study included an examination of mild depressive
symptoms, which are more prevalent among PD patients than are severe depressive symptoms.
The study confirmed that PD patients suffer from greater rates of both mild and moderate-severe
depressive symptoms than do non-PD patients, replicating prior findings (e.g., Althaus et al.,
2008).
In regard to the primary aim – to examine whether genetics contribute to the increased
risk of depressive symptoms among PD patients – the findings were consistent with a null
hypothesis for genetic influences upon the PD-depressive symptom relation. In addition to
findings from the cross-twin cross-trait tetrachoric correlations that did not suggest a genetic
effect on the relation between PD and depressive symptoms, the case control and co-twin control
results did not show a significant attenuation in the odds ratios for PD for either mild or
moderate-severe depressive symptoms. Furthermore, unaffected co-twin analyses indicated that
PD status in one’s co-twin did not predict depressive symptoms in the other twin, refuting a
genetic influence. These findings are an important contribution to studies of familial aggregation
of depression and PD (Arabia et al., 2007; Fahim et al., 1998), which have been inconclusive
regarding a shared genetic origin for the two disorders, by suggesting that a shared genetic origin
is unlikely.
The results of the present study indicate that environmental influences likely play an
important role in the etiology of depressive symptoms in individuals with Parkinson’s disease.
Possible non-genetic influences that may contribute to the development of PD-depression
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include psychosocial stressors associated with PD (e.g., sadness related to receiving a diagnosis
of a progressive illness), disease-related stressors (e.g., disability, pain), higher rates of
premorbid depression, and shared environmental factors that may contribute to the development
of both PD and depression (e.g., toxin exposure). Alternatively, brain changes associated with
PD that are not genetically influenced may heighten biological vulnerability to depressive
symptoms.
While the current study cannot elucidate the relative importance of various environmental
factors as opposed to possible increased biological vulnerability to depressive symptoms among
PD patients, the findings do provide additional evidence suggesting that PD patients with an
early age of PD onset experienced moderate-severe depressive symptoms at a higher rate
compared to PD patients with a later age of onset. This outcome is noteworthy from an
etiological standpoint not only because early age of PD onset is a documented risk factor for
depression in PD, but also because the one familial study supporting a shared genetic origin
between PD and depression (Arabia et al. 2007) concluded that the underlying familial
association was primarily driven by relatives of patients with a younger age of PD onset. Taken
together, this pattern of findings underscores the importance of examining the role of early age of
PD onset in the etiology of depressive symptoms in PD. In regard to the PD-depression
comorbidity, it is possible that a shared genetic origin is present for PD and depressive symptoms
only for patients with a younger age of PD onset.
The study also provides evidence for a genetic underpinning to both mild and moderatesevere depressive symptoms in late life, consistent with prior findings of heritability in late-life
depressive symptoms in other studies of Swedish twins (Jansson et al., 2004; Kendler, Gatz,
Gardner, & Pedersen, 2006b).
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Conclusions on Secondary Aims
Clinical presentation of PD-depression. To explore potential differences in depressive
symptom responding for PD versus non-PD individuals, ANCOVA analyses were conducted to
evaluate whether individual CESD-I item scores differed between individuals with versus
without PD. These analyses revealed that, compared to non-PD individuals with similar overall
depressive level, PD patients had higher scores on two of the eleven CESD-I items: sadness and
difficultly with the initiation to “get going.” The increased endorsement of sadness among PD
cases is consistent with prior research (Cummings, 1992; Slaughter, Slaughter, Nichols, Holmes,
& Martens, 2001) documenting that expression of sadness is one of the depressive symptoms
most frequently observed in PD-depression. The current finding that depressed PD patients
endorsed sadness above and beyond equally-depressed non-PD individuals may reflect the added
psychosocial stress of living with a progressive illness such as PD, and the associated increases
in quality of life factors such as disability and pain.
Although prior studies have not documented increased difficulty “getting going” in PDdepression compared to primary major depression, this finding is not surprising given that
fatigue often co-occurs with PD (Albin, 2006) and may affect one’s volition or energy.
Alternatively, the increased endorsement of difficulty “getting going” may be due to PD
symptoms of bradykinesia and rigidity, and therefore may simply reflect the nature of PD as a
movement disorder.
Other depressive symptoms considered to be more common among PD than non-PD
depressed patients, including irritability and difficulty concentrating, are not included on the
CESD-I scale. Future research evaluating how the clinical presentation of PD-depression may
differ from primary major depression will be useful in characterizing the unique expression of
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depression in PD, to ensure accurate diagnoses of PD-depression and appropriate tailoring of
depression treatments to this specific clinical presentation. The implications of the current
findings reinforce the importance of screening for depression among PD patients, particularly
those who evidence signs or complaints of sadness or avolition.
Early age of PD onset. Although the current study included only a small number of earlyonset PD cases, prevalence rates conducted separately for early-onset PD cases did provide some
support for the relation between early-age of PD onset and depressive symptoms. For moderatesevere level of depressive symptoms (CESD-I ≥ 9), individuals with an earlier age of PD onset
appeared to have a higher rate (35.29%) compared to individuals with a later age of PD onset
(22.08%). This outcome is consistent with prior literature that documents greater rates of
depression among early-onset PD patients compared to PD patients with a later age of onset
(Giladi et al., 2000; Starkstein et al., 1989). As the prior studies examining age of PD onset have
been conducted with clinical samples only, the current study provides some preliminary support
for a relation between PD-depressive symptoms and early-age of onset within a population-based
sample of PD patients. Additional studies will be useful in delineating whether this relation is
due to a different etiology of PD-depression for early-onset cases, or to psychosocial differences
(e.g., greater career disruption) that vary as a function of age of disease onset.
Strengths & Limitations
The strengths of the study include the utilization of a large, population-based sample with
reliable ascertainment of PD cases. The careful ascertainment of PD diagnosis, as validated by
movement disorder specialists, was a significant asset to the study. The identification of PD
cases was based on an extensive diagnostic process, which decreased measurement error and the
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risk of biases introduced by including various types of parkinsonism in the sample. The study
also utilized a valid measure of clinically significant depressive symptoms (Suthers et al., 2004).
The study was limited in the number of PD cases (i.e., 125) and by the low overall
concordance of PD in twin pairs. Because the sample included only three concordant PD pairs,
the lack of similarity between twins on PD rendered bivariate twin modeling uninformative. Had
the concordance rate been higher, bivariate twin modeling could have been conducted to reveal
relative estimates for the proportion of the PD-depressive symptom relation attributable to
genetic versus environmental influences. This limitation notwithstanding, the current study
represents the largest population-based twin sample of PD patients.
Finally, within the co-twin control sample, there may be pairs in which the non-PD twin
will later develop PD. However, the average number of years between age of onset of PD in the
PD twin and assessment of the non-PD twin was 7.4, slightly greater than the mean number of
years (7.0) separating PD age of onset for our three concordant pairs.
Conclusions
Understanding whether genetic influences contribute to the relation between PD and
depressive symptoms has the potential to inform both etiological theories and interventions. In
summary, the findings of these analyses suggest that genetic influences do not explain the
association between PD and mild or moderate-severe depressive symptoms. As such, future
etiology studies may be wise to focus on possible environmental factors that may explain this
relation.

41

References
Akaike, H. (1987). Factor analysis and AIC. Psychometrika, 52, 317-332.
Albin, R. L. (2006). Parkinson’s disease: background, diagnosis, and initial management. Clinics
in Geriatric Medicine, 22, 735-751.
Allott, R., Wells, A., Morrison, A. P., & Walker, R. (2005). Distress in Parkinson’s disease:
contributions of disease factors and metacognitive style. British Journal of Psychiatry,
187, 182-183.
Althaus, A., Becker, O. A., Spottke, A., Dengler, R., Schneider, F., Kloss, M., et al. (2008).
Frequency and treatment of depressive symptoms in a Parkinson’s disease registry.
Parkinsonism and Related Disorders, 14,626-632.
Arabia, G., Grossardt, B. R., Geda, Y., Carlin, J. M., Bower, J. H., Ahlskog, E., et al. (2007).
Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson
disease. Archives of General Psychiatry, 64, 1385-1392.
Barbas, N. R. (2006). Cognitive, affective, and psychiatric features of Parkinson’s disease.
Clinics in Geriatric Medicine, 22, 773-796.
Barrero, F. J., Ampuero, I., Morales, B., Vives, F., de Dios Luna del Castillo, J., Hoenicka, J., &
Yébenes, J. G. (2005). Depression in Parkinson’s disease is related to a genetic
polymorphism of the cannabinoid receptor gene (CNR1). The Pharmacogenomics
Journal, 5, 135-141.
Behari, M., Srivastava, A. K., Das, R. R., & Pandey, R. M. (2001). Risk factors of Parkinson’s
disease in Indian patients. Journal of the Neurological Sciences, 190, 49-55.
Behari, M., Srivastava, A. K., & Pandey, R. M. (2005). Quality of life in patients with
Parkinson’s disease. Parkinsonism and Related Disorders, 11, 221-226.

42

Bieliauskas, L. A., & Galntz, R. H. (1989). Depression type in Parkinson disease. Journal of
Clinical and Experimental Neuropsychology, 11, 597-604.
Broussole, E., Dentresangle, C., Landais, P., Garcia-Larrea, L., Pollak, P., Croisile, B., et al.
(1999). The relation of putamen and caudate nucleus 18F-dopa uptake to motor and
cognitive performances in Parkinson’s disease. Journal of Neurological Science, 166,
141-151.
Brown, R., & Jahanshahi, M. (1995). Depression in Parkinson’s disease: a psychosocial
viewpoint. In W. J. Weiner & A. E. Lang (Eds.), Behavioral neurology of movement
disorders (advances in neurology), vol 65 (pp. 61-84). New York: Raven Press.
Brown, R. G., MacCarthy, B., Gotham, A. M., Der, G. J., & Marsden, C. D. (1988). Depression
and disability in Parkinson’s disease: A follow-up of 132 cases. Psychological Medicine,
18, 49-55.
Burn, D. J. (2002). Depression in Parkinson’s disease. European Journal of Neurology, 9 (Suppl.
3), 44-54.
Burn, D. J., Tiangyou, W., Allcock, L. M., Davison, J., & Chinnery, P. F. (2006). Allelic
variation of a functional polymorphism in the serotonin transporter gene and depression
in Parkinson’s disease. Parkinsonism and Related Disorders, 12, 139-141.
Calne, S. M., Lidstone, S. C., & Kumar, A. (2008). Psychosocial issues in young-onset
Parkinson’s disease: current research and challenges. Parkinsonism and Related
Disorders, 14, 143-150.
Cantello, R., Aguggia, M., Gilli, M., Delsedime, I., Cutin, I. C., Riccio, A., et al. (1989). Major
depression in Parkinson’s disease and the mood response to intravenous methylphenidate:

43

possible role of the “hedonic” dopamine synapse. Journal of Neurology, Neurosurgery,
and Psychiatry, 52, 724-731.
Carpenter, J. S., Andrykowski, M. A., Wilson, J., Hall, L. A., Rayens, M. K., Sachs, B., et al.
(1998). Psychometrics for two short forms of the Center for Epidemiologic Studies –
Depression Scale. Issues in Mental Health Nursing, 19, 481-494.
Chen, J. J. (2004). Anxiety, depression, and psychosis in Parkinson’s disease: unmet needs and
treatment challenges. Neurologic Clinics, 22, S63-S90.
Cole, K., & Vaughan, F. L. (2005). The feasibility of using cognitive behavior therapy for
depression associated with Parkinson’s disease: A literature review. Parkinsonism and
Related Disorders, 11, 269-276.
Cole, S. A., Woodard, J. L., Juncos, J. L., Kogos, J. L., Youngstrom, E. A., & Watts, R. L.
(1996). Depression and disability in Parkinson’s disease. Journal of Neuropsychiatry
and Clinical Neurosciences, 8, 20-25.
Corcoran, K., & Fischer, J. (2000). Measures for clinical practice: A sourcebook, 3rd edition, vol.
2. Adults. New York: The Free Press.
Cubo, E., Bernard, B., Leurgans, S., & Raman, R. (2000). Cognitive and motor function in
patients with Parkinson’s disease with and without depression. Clinical
Neuropharmacology, 23, 331-334.
Cummings, J. L. (1992). Depression and Parkinson’s disease: a review. American Journal of
Psychiatry, 149, 443-454.
Cummings, J. L., & Masterman, D. L. (1999). Depression in patients with Parkinson’s disease.
International Journal of Geriatric Psychiatry, 14, 711-718.
de Lau, L. M., Giesbergen, P. C., de Rijk, M. C., Koudstaal, P. J., & Breteler, M. M. (2004).

44

Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam
Study. Neurology, 63, 1240-1244.
Devins, G. M., Orme, C. M., Costello, C. G., Binik, Y. M., et al. (1988). Measuring depressive
symptoms in illness populations: Psychometric properties of the Center for
Epidemiologic Studies Depression (CES-D) scale. Psychology & Health, 2, 139-156.
Dooneief, G., Mirabello, E., Bell, K., Marder, K., Stern, Y., & Mayeux, R. (1992). An estimate
of the incidence of depression in idiopathic Parkinson’s disease. Archives of Neurology,
49, 305-307.
Edwards, E., Kitt, C., Oliver, E., Finkelstein, J., Wagster, M., & McDonald, W. M. (2002).
Depression and Parkinson’s disease: a new look at an old problem. Depression and
Anxiety, 16, 39-48.
Ehmann, T. S., Beninger, R. J., Gawel, M. J., & Riopelle, R. J. (1990). Depressive symptoms in
Parkinson’s disease: A comparison with disabled control subjects. Journal of Geriatric
Psychiatry and Neurology, 3, 3-9.
Ehrt, U., Brønnick, K., Leentjens, A. F. G., Larsen, J. P., & Aarsland, D. (2006). Depressive
symptom profile in Parkinson’s disease: a comparison with depression in elderly patients
without Parkinson’s disease. International Journal of Geriatric Psychiatry, 21, 252-258.
Fahim, S., van Duijn, C. M., Baker, F. M., Launer, L., Breteler, M. M. B., Schudel, W. J., et al.
(1998). A study of familial aggregation of depression, dementia, and Parkinson’s disease.
European Journal of Epidemiology,, 14, 233-238.
Fahn, S., Elton, R. L., UPDRS program members. (1987). Unified Parkinson’s Disease Rating
Scale. In S. Fahn, C. D. Marsden, M. Goldstein, & D. B. Calne (Eds.), Recent

45

developments in Parkinson’s disease, vol 2 (pp. 153-163). Florham Park, NJ: Macmillan
Healthcare Information.
Fiske, A., Gatz, M., & Pedersen, N. L. (2003). Depressive symptoms and aging: the effects of
illness and non-health-related events. Journals of Gerontology: Series B: Psychological
Sciences and Social Sciences, 58, 320.
Fiske, A., & O’Riley, A. A. (2008). Assessment of depression in late life. In J. D. Hunsley &
E. J. Mash (Eds.), A guide to assessments that work (pp. 138-157). New York: Oxford
University Press.
Fukunishi, I., Hosokawa, K., & Ozaki, S. (1991). Depression antedating the onset of Parkinson’s
disease. The Japanese Journal of Psychiatry, 45, 7-11.
Gatz, M., Johansson, B., Pedersen, N., Berg, S., & Reynolds, C. (1993). A cross-national selfreport measure of depressive symptomatology. International Psychogeriatrics, 5, 147156.
Gatz, M., Mortimer, J. A., Fratiglioni, L., Johansson, B., Berg, S., Reynolds, C. A., et al. (2006).
Potentially modifiable risk factors for dementia in identical twins. Alzheimer’s &
Dementia, 2, 110-117.
Gatz, M., Pedersen, N. L., Plomin, R., Nesselroade, J. R., & McClearn, G. E. (1992). Importance
of shared genes and shared environments for symptoms of depression in older adults.
Journal of Abnormal Psychology, 101, 701-708.
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., et al. (2006).
Role of genes and environments for explaining Alzheimer disease. Archives of General
Psychiatry, 63, 168-174.
Giladi, N., Treves, T. A., Paleacu, D., Shabtai, H., Orlov, Y., Kandinov, B., et al. (2000). Risk

46

factors for dementia, depression and psychosis in long-standing Parkinson’s disease.
Journal of Neural Transmission, 107, 59-71.
Guze, B. H., & Barrio, J. C. (1991). The etiology of depression in Parkinson’s disease patients.
Psychosomatics: Journal of Consultation Liaison Psychiatry, 32, 390-395.
Hardy, J., Cai, H., Cookson, M. R., Gwinn-Hardy, K., & Singleton, A. (2006). Genetics of
Parkinson’s disease and parkinsonism. Annals of Neurology, 60, 389-398.
Himmelfarb, S., & Murrell, S. A. (1983). Reliability and validity of five mental health scales for
older persons. Journal of Gerontology, 38, 333-339.
Hoehn, M. M., & Yahr, M. D. (1967). Parkinsonism: onset, progression and mortality.
Neurology, 17, 427-442.
Horowitz, A., Reinhardt, J. P., & Kennedy, G. J. (2005). Major and subthreshold depression
among older adults seeking vision rehabilitation services. American Journal of Geriatric
Psychiatry, 13, 180-187.
Hubble, J. P., Cao, T., Hassanein, R. E., Neuberger, J. S., & Koller, W. C. (1993). Risk factors
for Parkinson’s disease. Neurology, 43, 1693-1697.
Hughes, T. A., Ross, H. F., Mindham, R. H. S., & Spokes, E. G. S. (2004). Mortality in
Parkinson’s disease and its association with dementia and depression. Acta Neurologica
Scandinavica, 110, 118-123.
Ishihara, L., & Brayne, C. (2006). A systematic review of depression and mental illness
preceding Parkinson’s disease. Acta Neurologica Scandinavica, 113, 211-220.
Jansson , M., Gatz, M., Berg, S., Johansson, B., Malmberg, B., McClearn, G. E., et al. (2004).
Gender differences in heritability of depressive symptoms in the elderly. Psychological
Medicine, 34, 471-479.

47

Kanner, A. M. (2005). Depression and the risk of neurological disorders. The Lancet, 366, 11471148.
Kendler, K., Gatz, M., Gardner, C. O., & Pedersen, N. L. (2006a). Personality and major
depression: a Swedish longitudinal, population-based twin study. Archives of General
Psychiatry, 63, 1113-1120.
Kendler, K., Gatz, M., Gardner, C. O., & Pedersen, N. L., (2006b). A Swedish national twin
study of lifetime major depression. American Journal of Psychiatry, 163, 109-114.
Kendler, K., Gardner, C. O., Gatz, M., & Pedersen, N. L. (2007). The sources of comorbidity
between major depression and generalized anxiety disorder in a Swedish national twin
sample. Psychological Medicine, 37, 453-462.
Kessler, R. C., Andrews, G., Mroczek, D., Üstün, B., & Wittchen, H-U. (1998). The World
Health Organization Composite International Diagnostic Interview short-form (CIDI-SF).
International Journal of Methods of Psychiatric Research, 7, 171-185.
Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman S., et al.
(1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the
United States: results from the National Comorbidity Survey. Archives of General
Psychiatry, 51, 8-19.
Koenig, H. G. (1997). Differences in psychosocial and health correlates of major and minor
depression in medically ill older adults. Journal of the American Geriatrics Society, 45,
1487-1495.
Kohout, F. J., Berkman, L. F., Evans, D. A., & Cornoni-Huntley, J. (1993). Two shorter forms
of the CES-D depression symptoms index. Journal of Aging and Health, 5, 179-193.
Kostic, V. S., Djuricic, B. M., Covickovic-Sternic, N., Bumbasirevic, L., Nikoloc, M., &

48

Mrsulja, B. B. (1987). Depression and Parkinson’s disease: possible role of serotonergic
mechanisms. Journal of Neurology, 234, 94-96.
Kremer, J., & Starkstein, S. E. (2000). Affective disorders in Parkinson’s disease. International
Review of Psychiatry, 12, 290-297.
Kuopio, A. M., Marttila, R. J., Helenius, H., Toivonen, M., & Rinne, U. K. (2000). The quality
of life in Parkinson’s disease. Movement Disorders, 15, 216-223.
Lauterbach, E. (2004). The neuropsychiatry of Parkinson’s disease and related disorders.
Psychiatric Clinics of North America, 27, 801-825.
Leentjens, A. F. G. (2004). Depression in Parkinson’s disease: conceptual issues and clinical
challenges. Journal of Geriatric Psychiatry and Neurology, 17, 120-126.
Leentjens, A. F. G., Lousberg, R., & Verhey, F. R. J. (2002). Markers for depression in
Parkinson’s disease. Acta Psychiatrica Scandinavica, 106, 196-201.
Leentjens, A. F. G., Scholtissen, B., Vreeling, F. W., & Verhey, F. R. (2006). The serotonergic
hypothesis for depression in Parkinson’s disease: an experimental approach.
Neuropsychopharmacology, 31, 1009-1015.
Leentjens, A. F. G., Van den Akker, M., Metsemakers, J. F. M., Lousberg, R., & Verhey, F. R. J.
(2003). Higher incidence of depression preceding the onset of Parkinson’s disease: a
register study. Movement Disorders, 18, 414-418.
Lewinsohn, P. M., Seeley, J. R., Roberts, R. E., Allen, N. B. (1997). Center for Epidemiologic
Studies Depression Scale (CES-D) as a screening instrument for depression among
community-residing older adults. Psychology & Aging, 12, 277-287.
Lichtenstein, P., De Faire, U., Floderus, B., Svartengren, M., Svedberg, P., & Pedersen, N. L.

49

(2002). The Swedish Twin Registry: a unique resource for clinical, epidemiological and
genetic studies. Journal of Internal Medicine, 252, 184-205.
Lieberman, A. (2006). Depression in Parkinson’s disease – a review. Acta Neurologica
Scandinavica, 113, 1-8.
Lin, D. Y. (1994). Cox regression analysis of multivariate failure time data: the marginal
approach. Stat Med, 13, 2233-2247.
Little, R. J. A., & Rubin, D. B. (2002). Statistical Analysis with Missing Data. New York: John
Wiley & Sons.
Mayberg, H. S., & Solomon, D. H. (1995). Depression in Parkinson’s disease: a biochemical and
organic viewpoint. In W. J. Weiner & A. E. Lang (Eds.), Behavioral neurology of
movement disorders (advances in neurology), vol 65 (pp. 49-60). New York: Raven
Press.
Mayeux, R. (1990). The “serotonergic hypothesis” for depression in Parkinson’s disease.
Advances in Neurology, 53, 163-166.
Mayeux, R., Stern, Y., Cote, L., & Williams, J. B. W. (1984). Altered serotonin metabolism in
depressed patients with Parkinson’s Disease. Neurology, 34, 642-646.
Mayeux, R., Stern, Y., Williams, J. B. W., Cote, L., Frantz, A., & Dyrenfurth, I. (1986). Clinical
and biochemical features of depression in Parkinson’s disease. American Journal of
Psychiatry, 143, 756-759.
Menza, M. A., Palermo, B., DiPaola, R., Sage, J. I., & Ricketts, M. H. (1999). Depression and
anxiety in Parkinson’s disease: possible effect of genetic variation in the serotonin
transporter. Journal of Geriatric Psychiatry & Neurology, 12, 49-52.
McCrone, P., Allcock, L. M., & Burn, D. J. (2007). Predicting the cost of Parkinson’s disease.

50

Movement Disorders, 22, 804-812.
McDonald, W. M., Richard, I. H., & DeLong, M. R. (2003). Prevalence, etiology, and treatment
of depression in Parkinson’s disease. Biological Psychiatry, 54, 363-375.
Merschdorf, U., Berg, D., Csoti, I., Fornadi, F., Merz, B., Naumann, M., et al. (2003).
Psychopathological symptoms of depression in Parkinson’s disease compared to major
depression. Psychopathology, 36, 221-225.
Middeldorp, C. M., Birley, A. J., Cath, D. C., Gillespie, N. A., Willemsen, G., Statham, D. J., et
al. (2005). Familial clustering of major depression and anxiety disorders in Australian
and Dutch twins and siblings. Twin Research and Human Genetics, 8, 609-615.
Moore, K. A., & Seeney, F. (2007). Biopsychosocial predictors of depressive mood in people
with Parkinson’s disease. Behavioral Medicine, 33, 29-37.
Murray, J. B. (1996). Depression in Parkinson’s disease. The Journal of Psychology, 130, 659667.
Neale, M. C. (1999). Statistical modeling with MX. Richmond: Medical College of Virginia,
Department of Human Genetics.
Neale, M. C., & Maes, H. H. (1997). Methodology for genetic studies of twins and families.
Dordrecht, Netherlands: Kluwer Academic Publishers.
Nilsson, F. M., Kessing, L. V., Sørensen, T. M., Andersen, P. K., & Bolwig, T. G. (2002). Major
depressive disorder in Parkinson’s disease: a register-based study. Acta Pscyhiatrica
Scandinavica, 106, 202-211.
Norman, S., Tröster, A. I., Fields, J. A., & Brooks, R. (2002). Effects of depression and
Parkinson’s disease on cognitive functioning. Journal of Neuropsychiatry and Clinical
Neurosciences, 14, 31-36.

51

Oehlberg, K., Barg, F. K., Brown, G., Taraborelli, D., Stern, M. B., & Weintraub, D. (2008).
Attitudes regarding the etiology and treatment of depression in Parkinson’s disease: a
qualitative study. Journal of Geriatric Psychiatry and Neurology, 21, 123-132.
Pedersen, N. L., Lichtenstein, P., & Svedberg, P. (2002). The Swedish Twin Registry in the third
millennium. Twin Research, 5, 427-432.
Plomin, R., DeFries, J. C., McClearn, G. E., & Rutter, M. (1997). Behavioral genetics, 3rd ed.
New York: W. H. Freeman and Company.
Prescott, C. A., Aggen, S. H., & Kendler, K. S. (2000). Sex-specific genetic influences on the
comorbidity of alcoholism and major depression in a population-based sample of US
twins. Archives of General Psychiatry, 57, 803-811.
Radloff, L.S. (1977). The CES-D scale: A self-report depression scale for research in the general
population. Applied Psychological Measurement, 1, 385-401.
Radloff, L. S., & Teri, L. (1986). Use of the Center for Epidemiological Studies-Depression
Scale with older adults. Clinical Gerontologist, 5, 119-136.
Rao, S. S., Hofmann, L. A., & Shakil, A. (2006). Parkinson’s disease: diagnosis and treatment.
American Family Physician, 74, 2046-2054.
Remy, P., Doder, M., Lees, A., Turjanski, N., & Brooks. D. (2005). Depression in Parkinson’s
disease: loss of dopamine and noradrenaline innervations in the limbic system. Brain,
128, 1314-1322.
Rhee, S. H., Hewitt, J. K., Lessem, J. M., Stallings, M. C., Corley, R. P., & Neale, M. C. (2004).
The validity of the Neale and Kendler model-fitting approach in examining the etiology
of comorbidity. Behavior Genetics, 34, 251-265.
Robinson, R. G., Chemerinski, E., & Jorge, R. (1999). Pathophysiology of secondary depressions

52

in the elderly. Journal of Geriatric Psychiatry and Neurology, 12, 128-136.
Rollman, B. L., & Reynolds, C. F. (1999). Minor and subsyndromal depression: functional
disability worth treating. Journal of the American Geriatrics Society, 47, 757-758.
Santamaria, J., Tolosa, E. S., Vallés, A. (1986a). Parkinson’s disease with depression: A possible
subgroup of idiopathic parkinsonism. Neurology, 36, 1130-1133.
Santamaria, J., Tolosa, E. S., Vallés, A., Bayes, A., Blesa, R., & Masana, J. (1986b). Mental
depression in untreated Parkinson’s disease of recent onset. Advances in Neurology, 45,
443-446.
Schneider, F., Althaus, A., Backes, V., & Dodel, R. (2008). Psychiatric symptoms in Parkinson’s
disease. European Archives of Psychiatry and Clinical Neuroscience, 258 [Suppl 5], 5559.
Schrag, A. (2004). Psychiatric aspects of Parkinson’s disease: an update. Journal of Neurology,
251, 795-804.
Schrag, A., Jahanshahi, M., & Quinn, N. P. (2000). What contributes to quality of life in patients
with Parkinson’s disease? Journal of Neurology, Neurosurgery, and Psychiatry, 69, 308312.
Schuurman, A. G., van den Akker, M., Ensinck, K. T., Metsemakers, J. F., Knottnerus, J. A.,
Leentjens, A. F., et al. (2002). Increased risk of Parkinson’s disease after depression: A
retrospective cohort study. Neurology, 58, 1501-1504.
Serrano-Dueñas, M. (2002). A comparison between low doses of amitriptyline and low doses of
fluoxetin used in the control of depression in patients suffering from Parkinson’s disease.
Reviews in Neurology, 35, 1010-1014.
Silberg, J. L., Heath, A. C., Kessler, R., Neale, M. C., Meyer, J. M., Eaves, L. J., & Kendler, K.

53

S. (1990). Genetic and environmental effects on self-reported depressive symptoms in a
general population twin sample. Journal of Psychiatric Research, 24, 197-212.
Simpson, J., Haines, K., Lekwuwa, G., Wardle, J., & Crawford, T. (2006). Social support and
psychological outcome in people with Parkinson’s disease: Evidence for a specific
pattern of associations. British Journal of Clinical Psychology, 45, 585-590.
Slaughter, J. R., Slaughter, K. A., Nichols, D., Holmes, S. E., & Martens, M. P. (2001).
Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s
disease. The Journal of Neuropsychiatry and Clinical Neurosciences, 13, 187-196.
Slawek, J., Derejko, M., & Lass, P. (2005). Factors affecting the quality of life of patients with
idiopathic Parkinson’s disease – a cross-sectional study in outpatient clinic attendees.
Parkinsonism & Related Disorders, 11, 465-468.
Starkstein, S. E., Berthier, M. L., Bolduc, P. L., Preziosi, T. J., & Robinson, R. G. (1989).
Depression in patients with early versus late onset of Parkinson’s disease. Neurology, 39,
1441-1445.
Starkstein, S. E., Merello, M., Jorge, R., Brockman, S., Bruce, D., Petracca, G., et al. (2008). A
validation study of depressive syndromes in Parkinson’s disease. Movement Disorders,
23, 538-546.
Starkstein, S. E., Petracca, G., Chemerinski, E., Teson, A., Sabe, L., Merello, M., et al. (1998).
Depression in classic versus akinetic-rigid Parkinson’s disease. Movement Disorders, 13,
29-33.
Starkstein, S. E., Preziosi, T. J., Bolduc, P. L., & Robinson, R. G. (1990). Depression in
Parkinson’s disease. The Journal of Nervous and Mental Disease, 178, 27-31.
Suthers, K. M., Gatz, M., & Fiske, A. (2004). Screening for depression: A comparative analysis

54

of the 11-item CES-D and the CIDI-SF. Journal of Mental Health and Aging, 10, 209219.
Tandberg, E., Larsen, J. P., Aarsland, D., & Cummings, J. L. (1996). The occurrence of
depression in Parkinson’s disease: a community-based study. Archives of Neurology,53,
175-179.
Tanner, C., Ellenberg, J., Mayeux, R., Ottman, R., & Langston, J. W. (1994). A sensitive and
specific screening method for Parkinson's disease (PD). Neurology, 44(Suppl 2), A136.
Taylor, A. E., & Saint-Cyr, J. A. (1990). Depression in Parkinson’s disease: reconciling
physiological and psychological perspectives. Neuropsychiatric Practice and Opinion, 2,
92-98.
Torack, R. M., & Morris, J. C. (1988). The association of ventral tegmental area histopathology
with adult dementia. Archives of Neurology, 45, 211-218.
Uekermann, J., Daum, I., Peters, S., Wiebel, B., Przuntek, H., & Müller, T. (2003). Depressed
mood and executive dysfunction in early Parkinson’s disease. Acta Neurologica
Scandinavica, 107, 341-348.
Vajda, F. J. E., & Solinas, C. (2005). Current approaches to management of depression in
Parkinson’s disease. Journal of Clinical Neuroscience, 12,739-743.
Veazey, C., Aki, S. O., Cook, K. F., Lai, E. C., & Kunik, M. E. (2005). Prevalence and treatment
of depression in Parkinson’s disease. Journal of Neuropsychiatry and Clinical
Neurosciences, 17, 310-323.
Warner, T. T., & Schapira, A. H. (2003). Genetic and environmental factors in the cause of
Parkinson’s disease. Annals of Neurology, 53, S16-S25.
Weintraub, D., Newberg, A. B., Cary, M. S., Siderowf, A. D., Moberg, P. J., Kleiner-Fisman, G.,

55

et al. (2005). Striatal dopamine transporter imaging correlates with anxiety and
depressive symptoms in Parkinson’s disease. Journal of Nuclear Medicine, 46, 227-232.
Wells, A., & Matthews, G. (1994). Attention and Emotion: A Clinical Perspective. Hillsdale, NJ:
Lawrence Erlbaum.
Wichowicz, H. M., Slawek, J., Derejko, M., & Cubala, W. J. (2006). Factors associated with
depression in Parkinson’s disease: a cross-sectional study in a Polish population.
European Psychiatry, 21, 516-520.
Widoe, R. K. (2007). Depression in Parkinson’s disease: A critical review of the literature
related to clinical characteristics of PD. Unpublished preliminary doctoral examination,
West Virginia University, Morgantown.
Wirdefeldt, K., Gatz, M., Bakaysa, S. L., Fiske, A., Flensburg, M., Petzinger, G. M., et al.
(2008). Complete ascertainment of Parkinson disease in the Swedish Twin Registry.
Neurobiology of Aging, 29, 1765-1773.
Wirdefeldt, K., Gatz, M., Schalling, M., & Pedersen, N. L. (2004). No evidence for heritability
of Parkinson disease in Swedish twins. Neurology, 63, 305-311.

56

Table 1
Sample Characteristics by Sex, Zygosity, and Age Group
Study population
N

All twins

49814

Sex
Men

22948 (46.07%)

Women

26866 (53.93%)

Zygosity a
MZ

10861 (21.80%)

DZ

17560 (35.25%)

OS

17413 (34.96%)

Unknown

3980 (7.99%)

Age group
50-59 years

23035 (46.24%)

60-69 years

13013 (26.12%)

70-70 years

9571 (19.21%)

80-89 years

3762 (7.55%)

90+ years

433 (0.87%)

a

MZ = monozygotic twins, DZ = same-sexed dizygotic twins, OS = opposite-sexed twins.
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Table 2
Clinical Diagnoses for Study Population (Wirdefeldt et al., 2008)
Diagnosis

N

PD
Possible PD

33

Probable PD

99

Parkinsonism
PSPa

6

MSAb

3

Cerebrovascular parkinsonism

32

Parkinsonism due to neuroleptics

11

Parkinsonism in dementia other than LBD

5

Parkinsonism of unknown cause

5

Other neurological diseases
Lewy body dementia

11

Cerebellar disease

6

Essential tremor

52

Other

c

6

No neurological disease

151

Total

420

a

PSP = Progressive supranuclear palsy
MSA = Multiple system atrophy
c
Includes restless legs, hereditary dystonia, polyneuropathy, tics
b
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Table 3
Prevalence of Mild and Moderate-Severe Depressive Symptom Cases by PD Status
_____________________________________________________________________________
No PD
PD
Chi-Square
(DF = 1)
_____________________________________________________________________________
CESD-I Total
4+

37.13% (12394/33377)

63.54% (61/96)

28.57**

9+

11.50% (3838/33377)

23.96% (23/96)

14.56**

_____________________________________________________________________________
** p < .0001
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Table 4
Probandwise Concordance Rates (N = 13,320 twin pairs)
___________________________________________________________________________
N Pairs concordant
Proportion Affected
Probandwise
unaffected: discordant:
concordance
concordant affected
rate
___________________________________________________________________________
Parkinson’s Disease (PD)
MZ a

3318 : 15 : 1

0.25%

11.8%

DZ

4754 : 34 : 2

0.40%

10.5%

OS

4551 : 28 : 0

0.31%

NA

___________________________________________________________________________
Mild Dep. Sym.b
MZ

1429 : 1205 : 557

36.34%

48.0%

DZ

1884 : 1884 : 736

37.26%

43.9%

OS

1793 : 1930 : 636

36.73%

39.7%

___________________________________________________________________________
Mod.-Severe Dep. Sym.c
MZ

2548 : 545 : 98

11.61%

26.5%

DZ

3552 : 850 : 102

11.70%

19.4%

OS

3478 : 818 : 63

10.83%

13.3%

___________________________________________________________________________
a

MZ = monozygotic twins, DZ = same-sexed dizygotic twins, OS = opposite-sexed twins.
Mild depressive symptoms = CESD-I score ≥ 4.
c
Moderate-severe depressive symptoms = CESD-I score ≥ 9.
b
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Table 5
Within-Trait Tetrachoric Correlations
___________________________________________________________________________
PD (N)

Mild
Moderate-Severe
b
Dep. Symptoms (N)
Dep. Symptomsc (N)
___________________________________________________________________________
Zygositya
MZ

0.59

(3334)

0.36 (3191)

0.30

(3191)

DZ

0.54

(4790)

0.20 (4504)

0.17

(4504)

OS

NA

(4579)

0.11 (4359)

0.09

(4359)

___________________________________________________________________________

a

MZ = monozygotic twins, DZ = same-sexed dizygotic twins, OS = opposite-sexed twins.
Mild depressive symptoms = CESD-I score ≥ 4.
c
Moderate-severe depressive symptoms = CESD-I score ≥ 9.
b
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Table 6
Cross-Twin Cross-Trait Tetrachoric Correlations
_____________________________________________________________________________
PD & Moderate-Severe
PD & Mild
b
Dep. Symptoms
Dep. Symptomsc
(N)
_____________________________________________________________________________
Zygositya
MZ

-0.08

0.06

(6445)

DZ

-0.11

0.04

(9181)

OS

-0.17

-0.10

(8847)

_____________________________________________________________________________

a

MZ = monozygotic twins, DZ = same-sexed dizygotic twins, OS = opposite-sexed twins.
Moderate-severe depressive symptoms = CESD-I score ≥ 9.
c
Mild depressive symptoms = CESD-I score ≥ 4.
b
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Table 7
Case control and co-twin control analyses predicting risk of moderate-severe depressive
symptoms (CESD-I ≥ 9)
Case control
______________________________________________________________________________________________
Cases (cesd ≥9)
Controls
OR (95% CI)
ORa (95% CI)
ORb (95% CI)
(N = 3861)
(N = 29,612)
______________________________________________________________________________________________
PD
23
73
2.37(1.34, 4.20)
2.64 (1.45, 4.78)
3.23(1.77, 5.89)
No-PD
3838
29,539

Co-twin control (N = 1395 monozygotic and dizygotic pairs)
______________________________________________________________________________________________
Cases (cesd ≥9)
Co-twin
OR (95% CI)
ORc (95% CI)
______________________________________________________________________________________________
PD
8
3
2.31 (1.29, 4.12)
3.15 (1.74, 5.67)
No-PD
1344
1376

Co-twin control monozygotic twins only (N = 545 monozygotic pairs)
______________________________________________________________________________________________
Cases (cesd ≥9)
Co-twin
OR (95% CI)
ORc (95% CI)
______________________________________________________________________________________________
PD
4
1
2.71 (0.97, 7.54)
3.43 (1.20, 9.82)
No-PD
523
537

a

Odds ratio controlling for age and sex.
Odds ratio controlling for age, sex, and prior history of major depression.
c
Odds ratio controlling for prior history of major depression.
b
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Table 8
Case control and co-twin control analyses predicting risk of mild depressive symptoms (CESD-I
≥ 4)
Case control
______________________________________________________________________________________________
Cases (cesd ≥4)
Controls
OR (95% CI)
ORa (95% CI)
ORb (95% CI)
(N = 12,455)
(N = 21,018)
______________________________________________________________________________________________
PD
61
35
2.96(1.76, 4.99)
3.16 (1.87, 5.33)
3.11 (1.82, 5.31)
No-PD
12,394
20,983

Co-twin control (N = 3089 monozygotic and dizygotic pairs)
______________________________________________________________________________________________
Cases (cesd ≥4)
Co-twin
OR (95% CI)
ORc (95% CI)
______________________________________________________________________________________________
PD
15
9
3.02 (1.81, 5.04)
3.22 (1.91, 5.41)
No-PD
3017
3061

Co-twin control monozygotic twins only (N = 1205 monozygotic pairs)
______________________________________________________________________________________________
Cases (cesd ≥4)
Co-twin
OR (95% CI)
ORc (95% CI)
______________________________________________________________________________________________
PD
4
4
1.56 (0.63, 3.85)
1.50 (0.59, 3.84)
No-PD
1179
1190

a

Odds ratio controlling for age and sex.
Odds ratio controlling for age, sex, and prior history of major depression.
c
Odds ratio controlling for prior history of major depression.
b
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Table 9
Presence of Individual Depressive Symptoms in Participants with and without PD
_____________________________________________________________________________
PD status F (p)
CESD-I Item
Model a F (df)
_____________________________________________________________________________
1. Depressed

4500.91 ** (4, 16785)

0.02 (p = .89)

2. Lonely

2580.33 ** (4, 16797)

0.07 (p = .79)

3. Sad

4251.85 ** (4, 16758)

4.93 (p = .03) *

4. Appetite

1160.29** (4, 16800)

2.55 (p = .11)

5. Effort

4188.64** (4, 16794)

0.18 (p = .67)

6. Slept fitfully

2242.65** (4, 16788)

1.16 (p = .28)

7. Couldn’t “get going”

2039.86** (4, 16747)

6.83 (p = .01) *

8. Happy

2614.86** (4, 16304)

2.07 (p = .15)

9. Enjoyed life

3119.40** (4, 16730)

3.51 (p = .06)

10. Unfriendly

579.61** (4, 16796)

3.58 (p = .06)

11. Disliked
576.11** (4, 16719)
0.21 (p = .65)
___________________________________________________________________________
a

Modeling PD status, with age, sex, and overall level of depressive symptoms as covariates
* = p < .05
* = p < .001
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Figure 1 Study design

SALT 1998 – 2002
(Pilot 1996)

SALT Population 50-65 years

SALT Population 65+ years

Dementia suspects
and co-twins,
controls and co-twins

SALT PD First Screening:
49,814 Eligible (< 50 yrs)
406 = died between selection and screening
8086 = refused
5125 = other non-participants (e.g., not interviewable)

Study of Dementia in
Swedish Twins (HARMONY)

36,197 = participated
(Participation rate 73.2%)

[Diagnostic Work-up for Dementia]

Self- or proxy-reported PD = 154
PD symptoms endorsed (suspects) = 577

1,557 = Dementia suspects with
diagnostic work-up

N = 577 PD suspects

PD Second Screening Phase:
Second telephone interview to exclude obvious non-PD

N = 154 self- or
proxy-reported PD
in first screening

577 PD suspects identified
68 = Dead or not willing to be contacted again
57 = Not contacted due to an administrative error

60 = PD suspects identified through
SALT and screened through
dementia work-up
53 = Excluded as PD suspects
through the HARMONY
neurological exam
34 = Additional PD suspects identified
by dementia work-up

452 = contacted for this phase
103 = Did not participate
349 participated (Participation rate = 77.2%)
182 = excluded directly by the exclusion algorithm
21 = excluded after review by study physician

N = 7 PD suspects
evaluated in
HARMONY

N = 34 PD suspects
from HARMONY

146 not excluded

PD Third Screening Phase: Medical

N = 146 PD suspects

Record Review
N = 188 (154 self- or proxy-reported PD
+ 34 PD suspects from HARMONY)
6 = excluded because diagnosis could not be
assigned due to insufficient info. (e.g., med.
records could not be obtained)

PD Third Screening Phase:
Somatic Exam & Medical Record Review
153 = eligible for this phase (146 from second
screening + 7 from HARMONY)
136 participated in this diagnostic work-up
19 = Did not participate;
11 = refused
7 = died after the second screening interview
1 = not worked up due to logistical difficulties

Final PD Diagnosis
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132 = PD cases identified (99 cases probable PD, 33 cases
possible PD)
125 = PD cases with PD onset before SALT
7 = excluded because PD onset was after SALT

Appendix A
Center for Epidemiologic Studies – Depression Scale Items

Participants were asked how often they experienced each of the following symptoms during the
last week. Responses were scored on a four-point scale:
0 = Rarely / None (Less than one day)
1 = Some / A little (1 to 2 days)
2 = Occasionally (3 to 4 days)
3 = Most / All the time (5 to 7 days)
1. I felt depressed.
2. I felt lonely.
3. I felt sad.
4. I didn’t feel like eating; I had a bad appetite.
5. Everything I did was an effort.
6. I slept fitfully.
7. I couldn’t “get going.”
8. I was happy.
9. I enjoyed life.
10. People were unfriendly.
11. I felt that people disliked me.
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Appendix B
Diagnostic Form for Parkinson’s Disease
(Y=yes, N=no, U=uncertain, IM=information missing)
NINDS Group A Features:
1. resting tremor (CAPIT)
2. bradykinesia (CAPIT)
3. rigidity (CAPIT)
4. asymmetric onset

Y
Y
Y
Y

N
N
N
N

U
U
U
U

IM
IM
IM
IM

NINDS Group B Features (Atypical Findings):
Y
N
U
IM
1. Features unusual early in the clinical course
a. Prominent postural instability in the first three years after symptom onset
b. Freezing phenomenon in the first three years
c. Hallucinations unrelated to medications in the first three years
d. Dementia preceding motor symptoms or in the first year
2. Supranuclear gaze palsy (other than restriction of upward gaze) or slowing of vertical saccades
3. Severe, symptomatic dysautonomia unrelated to medications
4. Documentation of condition known to produce parkinsonism and plausibly connected to the patient’s
symptoms (such as suitably located focal brain lesions or neuroleptic use within the past six months)
If U or Y : state finding ______________________________________________________

O Probable PD
A. At least three of the four features in Group A are present
and
B. None of the features in Group B is present (NOTE: symptom duration of at least three years is
necessary to meet this requirement)
and
C. Substantial and sustained response to levodopa or a dopamine agonist has been documented.
O Possible PD
A. At least two of the four features in Group A are present; at least one of these is tremor or
bradykinesia
and
B. Either
Or

1. None of the features in Group B is present
2. Symptoms have been present for less than three years and none of the features in
Group B is present to date

C. Either

1. Substantial and sustained response to levodopa or a dopamine agonist has been
documented
2. Patient has not had adequate trial of levodopa or a dopamine agonist.

and
Or
O Not PD
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